AU6874498A - Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses - Google Patents
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usesInfo
- Publication number
- AU6874498A AU6874498A AU68744/98A AU6874498A AU6874498A AU 6874498 A AU6874498 A AU 6874498A AU 68744/98 A AU68744/98 A AU 68744/98A AU 6874498 A AU6874498 A AU 6874498A AU 6874498 A AU6874498 A AU 6874498A
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- benzenesulfonyl
- hydroxy
- amino
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 239000003475 metalloproteinase inhibitor Substances 0.000 title description 2
- -1 4-(4-fluoro- phenoxy)benzenesulfonyl Chemical group 0.000 claims description 89
- 150000001875 compounds Chemical class 0.000 claims description 76
- 229960001639 penicillamine Drugs 0.000 claims description 58
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 36
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 239000000651 prodrug Substances 0.000 claims description 29
- 229940002612 prodrug Drugs 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 21
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 17
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 17
- 102000005741 Metalloproteases Human genes 0.000 claims description 17
- 108010006035 Metalloproteases Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- VDLVWWNTLVZUKM-UHFFFAOYSA-N CSC(C(=O)N)(CC)NS(=O)(=O)C1=CC=C(C=C1)OC1=CC=C(C=C1)Br Chemical compound CSC(C(=O)N)(CC)NS(=O)(=O)C1=CC=C(C=C1)OC1=CC=C(C=C1)Br VDLVWWNTLVZUKM-UHFFFAOYSA-N 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000003120 Angiofibroma Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000011675 Skin degenerative disease Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000009400 cancer invasion Effects 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 238000005160 1H NMR spectroscopy Methods 0.000 description 55
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 55
- 239000000243 solution Substances 0.000 description 45
- 239000007787 solid Substances 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 229910001868 water Inorganic materials 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000012267 brine Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 150000002431 hydrogen Chemical group 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 108091007196 stromelysin Proteins 0.000 description 7
- 102000043279 ADAM17 Human genes 0.000 description 6
- 108091007505 ADAM17 Proteins 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 102000004318 Matrilysin Human genes 0.000 description 5
- 108090000855 Matrilysin Proteins 0.000 description 5
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 5
- 102000044159 Ubiquitin Human genes 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 4
- XSMLYGQTOGLZDA-BYPYZUCNSA-N (2s)-2-amino-3-methyl-3-methylsulfanylbutanoic acid Chemical compound CSC(C)(C)[C@@H](N)C(O)=O XSMLYGQTOGLZDA-BYPYZUCNSA-N 0.000 description 3
- GOPUHTXVZGIOHN-UHFFFAOYSA-N 2,4-dihydroxybenzohydrazide Chemical compound NNC(=O)C1=CC=C(O)C=C1O GOPUHTXVZGIOHN-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 101150014058 MMP1 gene Proteins 0.000 description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 108700004333 collagenase 1 Proteins 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 3
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 3
- XHIRWEVPYCTARV-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(=O)NCCCN XHIRWEVPYCTARV-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YTSLULHGBPSVJQ-INIZCTEOSA-N (2r)-2-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-3,3-dimethylbutanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](C(C)(C)C)C(O)=O)=CC=C1OC1=CC=C(Cl)C=C1 YTSLULHGBPSVJQ-INIZCTEOSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- XOXRXINFTQAJBW-UHFFFAOYSA-N 4-(4-chlorophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 XOXRXINFTQAJBW-UHFFFAOYSA-N 0.000 description 2
- DXVIGUWDUVUVMI-UHFFFAOYSA-N 4-pyridin-4-yloxybenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1OC1=CC=NC=C1 DXVIGUWDUVUVMI-UHFFFAOYSA-N 0.000 description 2
- ILYZFHJHELGXFE-UHFFFAOYSA-N 4-pyridin-4-yloxybenzenesulfonyl chloride;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=NC=C1 ILYZFHJHELGXFE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XYSUTVOOHCBBCN-UHFFFAOYSA-N BrC1=CC=C(OC2=CC=C(C=C2)S(=O)(=O)NC(C(=O)N)CC)C=C1 Chemical compound BrC1=CC=C(OC2=CC=C(C=C2)S(=O)(=O)NC(C(=O)N)CC)C=C1 XYSUTVOOHCBBCN-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DUHKRLSCLIKDKS-UHFFFAOYSA-N FC1=CC=C(OC2=CC=C(C=C2)S(=O)(=O)NC(C(=O)N)CC)C=C1 Chemical compound FC1=CC=C(OC2=CC=C(C=C2)S(=O)(=O)NC(C(=O)N)CC)C=C1 DUHKRLSCLIKDKS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- KIGALSBMRYYLFJ-UHFFFAOYSA-N chloro-(2,3-dimethylbutan-2-yl)-dimethylsilane Chemical compound CC(C)C(C)(C)[Si](C)(C)Cl KIGALSBMRYYLFJ-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- 230000008354 tissue degradation Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DUHKRLSCLIKDKS-HNNXBMFYSA-N (2S)-2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]butanamide Chemical compound FC1=CC=C(OC2=CC=C(C=C2)S(=O)(=O)N[C@H](C(=O)N)CC)C=C1 DUHKRLSCLIKDKS-HNNXBMFYSA-N 0.000 description 1
- AQUABPPIOGHIBU-INIZCTEOSA-N (2r)-2-[[4-(4-bromophenoxy)phenyl]sulfonylamino]-3,3-dimethylbutanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](C(C)(C)C)C(O)=O)=CC=C1OC1=CC=C(Br)C=C1 AQUABPPIOGHIBU-INIZCTEOSA-N 0.000 description 1
- JTCSGIYCFBCQMR-MRXNPFEDSA-N (2r)-2-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-3-methylbutanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](C(C)C)C(O)=O)=CC=C1OC1=CC=C(Cl)C=C1 JTCSGIYCFBCQMR-MRXNPFEDSA-N 0.000 description 1
- LDYKRMJEFNIWLO-INIZCTEOSA-N (2r)-2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-3,3-dimethylbutanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](C(C)(C)C)C(O)=O)=CC=C1OC1=CC=C(F)C=C1 LDYKRMJEFNIWLO-INIZCTEOSA-N 0.000 description 1
- NPDBDJFLKKQMCM-BYPYZUCNSA-N (2r)-2-azaniumyl-3,3-dimethylbutanoate Chemical compound CC(C)(C)[C@@H]([NH3+])C([O-])=O NPDBDJFLKKQMCM-BYPYZUCNSA-N 0.000 description 1
- UVINDFAMLDFNEB-INIZCTEOSA-N (2r)-3,3-dimethyl-2-[(4-phenoxyphenyl)sulfonylamino]butanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](C(C)(C)C)C(O)=O)=CC=C1OC1=CC=CC=C1 UVINDFAMLDFNEB-INIZCTEOSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IOOCHXMDSFPOGL-UHFFFAOYSA-N 1-benzyl-2-chloromethylimidazole hydrochloride Chemical compound [H+].[Cl-].ClCC1=NC=CN1CC1=CC=CC=C1 IOOCHXMDSFPOGL-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- SSTNIXFHCIOCJI-UHFFFAOYSA-N 1-methyl-4-phenoxybenzene Chemical compound C1=CC(C)=CC=C1OC1=CC=CC=C1 SSTNIXFHCIOCJI-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- MEAAWTRWNWSLPF-UHFFFAOYSA-N 2-phenoxypyridine Chemical compound C=1C=CC=NC=1OC1=CC=CC=C1 MEAAWTRWNWSLPF-UHFFFAOYSA-N 0.000 description 1
- RPUPONKYWKGYKA-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-1,2-bis(propylsulfonyl)indolizine-6-carboxamide Chemical compound N12C=C(C(N)=O)C=CC2=C(S(=O)(=O)CCC)C(S(=O)(=O)CCC)=C1C(=O)C1=CC=C(F)C=C1 RPUPONKYWKGYKA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PLFIHRLMNDKZGJ-UHFFFAOYSA-N 4-(4-bromophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=C(Br)C=C1 PLFIHRLMNDKZGJ-UHFFFAOYSA-N 0.000 description 1
- NPBRNBLZNUPDMG-UHFFFAOYSA-N 4-(4-cyanophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=C(C#N)C=C1 NPBRNBLZNUPDMG-UHFFFAOYSA-N 0.000 description 1
- PDAYRCHIAPCRRD-UHFFFAOYSA-N 4-(4-fluorophenoxy)benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 PDAYRCHIAPCRRD-UHFFFAOYSA-N 0.000 description 1
- INXLITRVKMFIGU-UHFFFAOYSA-N 4-(4-methylphenoxy)benzenesulfonyl chloride Chemical compound C1=CC(C)=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 INXLITRVKMFIGU-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- MYPXYQMABPTFFN-UHFFFAOYSA-N 4-phenoxybenzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1OC1=CC=CC=C1 MYPXYQMABPTFFN-UHFFFAOYSA-N 0.000 description 1
- OATKXQIGHQXTDO-UHFFFAOYSA-N 4-phenoxypyridine Chemical compound C=1C=NC=CC=1OC1=CC=CC=C1 OATKXQIGHQXTDO-UHFFFAOYSA-N 0.000 description 1
- SIXGMZJXZNKUIN-UHFFFAOYSA-N 4-phenylsulfanylpyridine Chemical compound C=1C=NC=CC=1SC1=CC=CC=C1 SIXGMZJXZNKUIN-UHFFFAOYSA-N 0.000 description 1
- CXLPHVTZYYDWQX-UHFFFAOYSA-N 4-pyridin-2-yloxybenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=CC=N1 CXLPHVTZYYDWQX-UHFFFAOYSA-N 0.000 description 1
- KEKFFDJBZFRDOS-UHFFFAOYSA-N 4-pyridin-4-ylsulfanylbenzenesulfonyl chloride;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)Cl)=CC=C1SC1=CC=NC=C1 KEKFFDJBZFRDOS-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108030004510 Interstitial collagenases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000005957 chlorosulfonylation reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 102000052074 human MMP7 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- ITHGGMSDPOKFOA-WCCKRBBISA-N methyl (2s)-2-amino-3-methyl-3-sulfanylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)C(C)(C)S ITHGGMSDPOKFOA-WCCKRBBISA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- PCOHQBAAXINNOQ-UHFFFAOYSA-N n-hydroxy-2-[(4-methylphenyl)sulfonylamino]acetamide Chemical compound CC1=CC=C(S(=O)(=O)NCC(=O)NO)C=C1 PCOHQBAAXINNOQ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Metalloproteinase Inhibitors, Pharmaceutical Compositions Containing Them and Their Pharmaceutical Uses
The present invention relates to compounds that inhibit metalloproteinases, particularly matrix metalloproteinases and tumor necrosis factor-α convertase, and their pharmaceutically acceptable salts and pharmaceutically acceptable prodrugs. The invention further relates to the uses of these compounds, salts and prodrugs for the therapeutic treatment of humans or animals.
Matrix metalloproteinases ("MMPs") are a family of enzymes, including, but not limited to, collagenases, gelatinases, matrilysin, and stromelysins, which are involved in the degradation and remodelling of connective tissues. These enzymes are found in a number of cell types that are found in or associated with connective tissue, such as fibroblasts, monocytes, macrophages, endothelial cells and metastatic tumor cells. They also share a number of properties, including zinc and calcium dependence, secretion as zymogens, and 40-50% amino acid sequence homology.
Matrix metalloproteinases degrade the protein components of the extracellular matrix, i.e. the protein components found in the linings of joints, interstitial connective tissue, basement membranes, cartilage and the like. These proteins include collagen, proteoglycan, fibronectin and lamanin.
Collagen is the major structural protein of mammalian tissue, comprising one- third of the total protein in mammalian organisms, and is an essential component of many matrix tissues, including cartilage, bone, tendons and skin. Interstitial collagenases catalyze the initial (rate-limiting) cleavage of native collagen types I, II, III and X. These enzymes cleave collagen into two fragments which spontaneously denature at physiological temperature. Denaturation of collagen involves conversion of the rigidly coiled helix to a random coil referred to as gelatin. These gelatin (denatured collagen) fragments are then subject to further cleavage and degradation by less specific enzymes. The net result of collagenase cleavage is thus the loss of structural integrity in the matrix tissue (collagen collapse), an essentially irreversible process.
The gelatinases include two distinct yet highly related enzymes: a 72- kiloDalton (kDa) enzyme and a 92-kiloDalton enzyme. The former is released by fibroblasts while the latter is released by mononuclear phagocytes, neutrophils,
corneal epithelial cells, tumor cells, cytotrophoblasts and keratinocytes. Both enzymes degrade gelatins (denatured collagens), collagen types IV (basement membrane) and V, fibronectins (high molecular weight multifunctional glycoproteins found in soft connective tissue and basement membranes) and insoluble elastin (highly cross-linked hydrophobic proteins found in load bearing fibers of mammalian connective tissue).
Stromelysins (1 and 2) cleave a broad range of matrix substrates, including lamanin, fibronectins, proteoglycans and collagen types IV and IX (non-helical).
Matrilysin (putative metalloproteinase or PUMP) also degrades a wide variety of matrix substrates, including proteoglycans, gelatins, fibronectins, elastins and lamanin. Matrilysin has been found in mononuclear phagocytes, rat uterine explants and tumor cells.
In normal tissues, the activity of matrix metalloproteinases is tightly regulated. As a result, the breakdown of connective tissue mediated by these enzymes is generally in a dynamic equilibrium with synthesis of new matrix tissue.
In a number of pathological disease conditions, however, deregulation of matrix metalloproteinase activity leads to the uncontrolled breakdown of extracellular matrix. These disease conditions include arthritis (e.g., rheumatoid arthritis and osteoarthritis), periodontal disease, aberrant angiogenesis, tumor metastasis and invasion, tissue ulceration (e.g., corneal ulceration, gastric ulceration or epidermal ulceration), bone disease, HIV-infection and complications from diabetes.
Administration of matrix metalloproteinase inhibitors has been found to reduce the rate of connective tissue degradation, thereby leading to a favorable therapeutic effect. For example, in Cancer Res., vol. 53, p. 2087 (1993), a synthetic matrix metalloproteinase inhibitor was shown to have in vivo efficacy in a murine model for ovarian cancer with an apparent mode of action consistent with inhibition of matrix remodelling. The design and uses of MMP inhibitors are reviewed, for example, in J. Enzyme Inhibition, 2, 1-22 (1987); Progress in Medicinal Chemistry 29, 271-334 (1992); Current Medicinal Chemistry, 2, 743-762 (1995); Exp. Opin. Ther. Patents, 5, 1287-1296 (1995); and Drug Discovery Today, 1 , 16-26 (1996).
Matrix metalloproteinase inhibitors are also the subject of numerous patents and patent applications, including: U.S. Patent No. 5,189,178; U.S. Patent No. 5,183,900; U.S. Patent No. 5,506,242; U.S. Patent No. 5,552,419; U.S. Patent No.
5,455,258; European Patent Application No. 0 438 223; European Patent Application No. 0 276 436; WIPO International Publication No. WO 92/21360; WIPO International Publication No. WO 92/06966; WIPO International Publication No. WO 92/09563; WIPO International Publication No. WO 96/00214; WIPO International Publication No. 95/35276; WIPO International Publication No. WO 96/27583, and WIPO International Publication No. WO 96/33172, the disclosures of each of which are incorporated herein by reference.
Tumor necrosis factor-** ("TNF-α") is a cytokine which is produced as a 28- kDa precursor and released in an active 17-kDa form. This active form can mediate a large number of deleterious effects in vivo, including inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration of TNF-α can cause cachexia and anorexia; accumulation of excess of TNF-α can be fatal.
TNF-α convertase is a metalloproteinase involved in the biosynthesis of TNF- α. Inhibition of TNF-α convertase inhibits production of TNF-α.
Since excessive TNF-α production has been noted in several disease conditions characterized by MMP-mediated tissue degradation, including multiple sclerosis, arthritis and cancer, compounds which inhibit both MMPs and TNF-α convertase are especially advantageous for the treatment or prophylaxis of disease conditions in which both mechanisms are involved. Although compounds that both inhibit MMPs activity and TNF-α production have been disclosed in WIPO International Publication Nos. WO 94/24140 and WO 94/02466, the disclosures of which are herein incorporated by reference, there is still a need for effective MMP and/or TNF-α convertase inhibiting agents.
Because of their beneficial therapeutic effects, there is a need for effective inhibitors of metalloproteinase activity. The present invention is therefore directed to certain compounds that inhibit metalloproteinases, such as MMPs and TNF-α convertase, their pharmaceutically acceptable prodrugs, salts and solvates, pharmaceutical compositions containing the same and methods of using the same, as well as to method and intermediates useful in their preparation. Additional features and advantages of the invention will be set forth in the description which
follows, and in part will be apparent from the description or may be learned from practice of the invention.
To achieve these and other advantages, the present invention provides a compound of formula I:
wherein Y is O or S; Ar is an aryl group or a heteroaryl group; R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or -C OJR^ wherein R is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR2R3, wherein R2 and R3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; and X is -NH-OH or -OH, or a pharmaceutically acceptable prodrug, salt or solvate thereof.
The present invention is also directed to a pharmaceutical composition comprising (a) a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt or solvate thereof; and (b) a pharmaceutically acceptable carrier, diluent, vehicle or excipient.
The present invention is further directed to a method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable prodrug, salt or solvate thereof. More particulaly, the present invention is directed to a method of treating tumor growth, invasion or metastasis, osteoarthritis, rheumatoid arthritis, osteoporosis, periodontitis, gingivitis, chronic dermal wounds, corneal ulceration, degenerative skin disorders, multiple sclerosis, stroke, atherosclerosis, glomerular disease, Alzheimer's disease, or a disease condition characterized by unwanted angiogenesis, such as diabetic retinopathy, macular degeneration, angiofibromas, or hemangiomas.
The present invention is still further directed to a method of inhibiting the activity of a metalloproteinase that comprises contacting the metalloproteinase with
an effective amount of a compound of formula (I) or a pharmaceutically acceptable prodrug, salt or solvate thereof.
As used in the present application, the following definitions apply, unless otherwise indicated:
An "alkyl group" is intended to mean a straight or branched chain monovalent radical of saturated and/or unsaturated carbon atoms and hydrogen atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, pentenyl, butenyi, propenyl, ethynyl, butynyl, propynyl, pentynyl, hexynyl, and the like, which may be unsubstituted (i.e., containing only carbon and hydrogen) or substituted by one or more suitable substituents as defined below.
An "O-alkyl group" or "alkoxy group" is intended to mean an oxygen bonded to an alkyl group, wherein the alkyl group is as defined above.
A "cycloalkyl group" is intended to mean a non-aromatic, monovalent monocyciic, bicyclic, or tricyclic radical containing 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, or 14 carbon ring atoms, each of which may be saturated or unsaturated, and which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more heterocycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1.]heptyl, bicyclo[2.2.1.]hept-2-en-5- yl, bicyclo[2.2.2]octyl, bicyclo[3.2.1.]nonyl, bicyclo[4.3.0]nonyl, bicyclo[4.4.0]decyl, indan-1-yl, indan-2-yl, tetralin-1-yl, tetralin-2-yl, adamantyl, and the like.
A "heterocycloalkyl group" is intended to mean a non-aromatic, monovalent monocyciic, bicyclic, or tricyclic radical, which is saturated or unsaturated, containing 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, or 18 ring atoms, and which includes 1 , 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen and sulfur, wherein the radical is unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, aryl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of heterocycloalkyl groups include, but are not limited to, azetidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, tetrahydro-2H-1 ,4-thiazinyl, tetrahydrofuryl, dihydrofuryl, tetrahydropyranyi,
dihydropyranyl, 1 ,3-dioxolanyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl, 1 ,3-oxathiolanyl, 1 ,3- oxathianyl, 1 ,3-dithianyl, azabicylo[3.2.1]octyl, azabicylo[3.3.1]nonyl, azabicylo[4.3.0]nonyl, oxabicylo[2.2.1]heptyl, 1 ,5,9-triazacyclododecyl, and the like.
An "aryl group" is intended to mean an aromatic, monovalent monocyciic, bicyclic, or tricyclic radical containing 6, 10, 14, or 18 carbon ring atoms, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluoren-2-yl, indan-5-yl, and the like.
A "heteroaryl group" is intended to mean an aromatic monovalent monocyciic, bicyclic, or tricyclic radical containing 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 1 , 2, 3, 4, or 5 heteroatoms selected from nitrogen, oxygen and sulfur, which may be unsubstituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Illustrative examples of heteroaryl groups include, but are not limited to, pyrrolyl, imidazoiyl, pyrazolyl, furyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, benzofuryl, isobenzofuryl, benzothienyl, quinolyl, isoquinolyl, phthalazinyl, carbazolyl, purinyl, pteridinyl, acridinyl, phenanthrolinyl, phenoxazinyl, phenothiazinyl, and the like.
An "acyl group" is intended to mean a -C(0)-R5- radical, wherein R5 is any suitable substituent as defined below.
A "sulfonyl group" is intended to mean a -S(0)(0)-R5- radical, wherein R5 is any suitable substituent as defined below.
The term "suitable substituent" is intended to mean any of the substituents recognizable to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds. Illustrative examples of suitable substituents include, but are not limited to, oxo groups, alkyl groups, hydroxy groups, halo groups, cyano groups, nitro groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, trialkylsilyl groups,
groups of formula (A)
wherein Ra is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (B)
wherein Ra is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (C)
O
I
Re
wherein Rb and Rc are independently hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (D)
Λ
N
(D)
A^ ■Re
wherein Rd is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group, or an acylamino group; and Re is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an amino group, an alkylamino group, or a dialkylamino group,
groups of formula (E)
O
— S— R. (E)
II O wherein Rf is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (F)
wherein Rg and Rh are independently hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, groups of formula (G)
\<y.R. (G)
wherein R, is an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (A), formula (B), formula (C), formula (H) (defined below), or formula (K) (defined below), groups of formula (H)
^N/Rk (H)
I
R. wherein Rt is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, or a group of formula (A), formula (B), formula (C) or formula (D); and wherein Rk is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (A), formula (B), formula (C), formula (D), formula (E), or formula (F), groups of formula (J)
wherein R, is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or a group of formula (C), and groups of formula (K)
herein Rm and Rn are independently an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a hydroxy group, an alkoxy group, an amino group, an alkylamino group, or a dialkylamino group.
The term "suitable organic moiety" is intended to mean any organic moiety recognizable to those skilled in the art as not adversely affecting the inhibitory activity of the inventive compounds. Illustrative examples of suitable organic moieties include, but are not limited to oxo groups, alkyl groups, hydroxy groups, halo groups, cyano groups, nitro groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, trialkylsilyl groups, and groups of formulas (A), (B), (C), (D), (E), (F), (G), (H), (J), and (K), as defined above.
A "hydroxy group" is intended to mean the radical -OH.
An "oxo group" is intended to mean the divalent radical =0.
A "halo group" or is intended to mean any of the radicals -F, -Cl, -Br, or -I.
A "cyano group" is intended to mean the radical -CΞN.
A "nitro group" is intended to mean the radical -N02.
A "trialkylsilyl group" is intended to mean the radical -SiRpRqRs, where Rp, Rq, and Rs are each independently an alkyl group.
A "carboxy group" is intended to mean a group of formula (B) wherein Ra is hydrogen.
A "alkoxycarbonyl group" is intended to mean a group of formula (B) wherein Ra is an alkyl group as defined above.
A "carbamoyl group" is intended to mean a group of formula (C) wherein Rb and Rc are both hydrogen.
An "amino group" is intended to mean the radical -NH2.
An "alkylamino group" is intended to mean the radical -NHRU, wherein Ru is an alkyl group as defined above.
A "dialkylamino group" is intended to mean the radical -NRURV, wherein Ru and Rv, which are the same or different, are each an alkyl group as defined above.
A "pharmaceutically acceptable prodrug" is intended to mean a compound that is converted under physiological conditions or by soivolysis to a compound of the formula I.
A "pharmaceutically acceptable solvate" is intended to mean a solvate that retains the biological effectiveness and properties of the biologically active components of compounds of formula I.
Examples of pharmaceutically acceptable solvates include, but are not limited to, compounds of formula I in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
In the case of solid formulations, it is understood that the inventive compounds may exist in different forms, such as stable and metastable crystalline forms and isotropic and amorphous forms, all of which are intended to be within the scope of the present invention.
A "pharmaceutically acceptable salt" is intended to mean those salts that retain the biological effectiveness and properties of the free acids and bases and that are not biologically or otherwise undesirable.
Examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1 ,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxyenzoates, phthalates, sulfonates, xylenesulfonates, phenyiacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1 -sulfonates, naphthalene-2- sulfonates, and mandelates.
If the inventive compound is a base, the desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosidyl acids such as glucuronic acid and galacturonic acid, alpha-hydroxy acids such as citric acid and tartaric acid, amino acids such as aspartic acid and glutamic acid, aromatic acids such as benzoic acid and cinnamic acid, sulfonic acids such a p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the inventive compound is an acid, the desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal or alkaline earth metal hydroxide or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
The inventive compounds may exist as single stereoisomers, racemates and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention. Preferably the inventive compounds, and prodrugs, salts and solvates thereof, have the formula la:
As generally understood by those skilled in the art, an optically pure compound having one chiral center (i.e., one asymmetric carbon atom) is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure. Preferably, the compounds of the present invention are used in a form that is at least 90% optically pure, that is, a form that contains at least 90% of a single isomer (80% enantiomeric
excess ("e.e.") or diastereomeric excess ("d.e.")), more preferably at least 95% (90% e.e. or d.e.), even more preferably at least 97.5% (95% e.e. or d.e.), and most preferably at least 99% (98% e.e. or d.e.).
In the compounds, compositions and methods of the present invention, preferably Ar is an aryl group substituted with a suitable substitutent, as defined above, in the position para to the Y moiety. Preferably the suitable substituent is a halogen, an alkyl group, an O-alkyl group, an aryl group, a heteroaryl group, or an S- alkyl group.
Additionally it is preferred that R is an alkyl group, preferably the alkyl group -(CH3)2-S-alkyl, and still more preferably the alkyl group -C(CH3)2-S-CH2-heteroaryl.
Particularly preferred compounds falling within formula I include:
2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)- aminojbutanamide,
2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)- aminojbutanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-fluoro- phenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-bromophenoxy)- benzenesulfonyl)amino]butanamide,
N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(1-benzyl-1 H-imidazol-2- yl)methyl]-D-penicillamine,
N-[4-(4-lodophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D-penicillamine,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-iodophen- oxy)benzenesulfonyl)amino]butanamide,
N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(5-methylisoxazol-3-yl)methyl]-D- penicillamine,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4- fluorophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-methyl- phenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(pyrid- -yloxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-{(pyrid- -yl)sulfanyl}benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 H-imidazol-4-yl)methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-2-yl) methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-4-yl) methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(4-methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl-2- [(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl-2- [(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide, and
2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4-(4-chlorophenoxy)benzene- sulfonyl)amino]butanamide; and pharmaceutically acceptable prodrugs, salts, and solvates thereof.
The present invention is further directed to methods of inhibiting metalloproteinase activity, for example in mammalian tissue, by administering a compound of the formula I, or a pharmaceutically acceptable prodrug, salt or solvate thereof. The activity of the inventive compounds as inhibitors of metalloproteinases, such as MMPs (including stromelysins, collagenases, gelatinases and/or matrilysin) and/or TNF-« convertase, may be measured by any of the methods available to those skilled in the art, including in vivo and/or in vitro assays. Examples of suitable assays for activity measurements include those described in Anal. Biochem., vol. 147, p. 437 (1985), Anal. Biochem., vol. 180, p. 110 (1989), FEBS, vol. 96, p. 263 (1992) and European Patent Application No. 0 606 046.
Administration of the compounds of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates, may be performed according to any of the accepted modes of administration available to those skilled in the art. Illustrative examples of suitable modes of administration include oral, nasal, parenteral, topical, transdermal and rectal. Preferably, the mode of administration is oral.
The inventive compounds of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates, may be administered as a pharmaceutical composition in any suitable pharmaceutical form recognizable to the skilled artisan. Suitable pharmaceutical forms include, but are not limited to, solid, semisolid, liquid or lyophilized formulations, such as tablets, powders, capsules, suppositories, suspensions and aerosols. Preferably, the pharmaceutical form is a tablet or capsule for oral administration. The pharmaceutical composition may also include suitable excipients, diluents, vehicles and carriers as well as other pharmaceutically active agents, depending upon the intended use.
Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions are known to those skilled in the art. For example, pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural and/or rectal administration. Illustrative examples of such methods include those described in Remington's Pharmaceutical Sciences, 18th edition (1990).
Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles or excipients may be employed in the pharmaceutical compositions. Illustrative solid carriers include starch, lactose, calcium sulphate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g. solution), or a nonaqueous or aqueous liquid suspension.
A dose of the pharmaceutical composition contains at least a therapeutically effective amount of the active compound (i.e., a compound of the formula I, or a pharmaceutically acceptable prodrug, salt or solvate thereof) and preferably is made up of one or more pharmaceutical dosage units. An exemplary dosage unit for a mammalian host contains an amount of from 0.1 milligram up to 500 milligrams of
active compound per kilogram body weight of the host, preferably 0.1 to 200 milligrams, more preferably 50 milligrams or less, and even more preferably about 10 milligrams or less, per kilogram of the host weight. The selected dose may be administered to a mammal, for example, a human patient in need of treatment mediated by inhibition of metalloproteinase activity, by any known method of administrating the dose including: topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; or continuously by intravaginal, intranasal, intrabronchial, intraaural or intraocular infusion.
The amount of the inventive compounds, salts, solvates and/or prodrugs to be administered will vary based upon a number of factors, including the specific metalloproteinase to be inhibited, the degree of inhibition desired, the characteristics of the mammalian tissue in which inhibition is desired, the metabolic stability and activity of the particular inventive compound employed, and the mode of administration. One skilled in the art may readily determine a suitable dosage according to methods known to the art. Preferably, the amount of inventive compound of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates, administered ranges from 0.1 mg/kg body weight to 100 mg/kg body weight per day.
The inventive compounds, and the salts, solvates, and prodrugs thereof, may be prepared by employing the techniques available in the art using starting materials that are readily available. Exemplary methods of preparing the inventive compounds are described below. In the following schemes, unless otherwise indicated, R, Ar and Y are as previously defined herein.
Scheme 1
As illustrated in Scheme 1 , hydroxamic acids of formula II (i.e., compounds of Formula I, where X is NH-OH) can be prepared by reacting the corresponding carboxylic acids of formula III, (i.e., compounds of formula I, where X = OH) with hydroxylamine in the presence of a suitable peptide coupling reagent, for example, 1 ,1'-carbonyldimidazole, N-(dimethylaminopropyl)-N'-ethyl carbodiimide, benzotriazol- 1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, or propane- phosphonic anhydride in an inert polar solvent, such as dimethylformamide. Alternatively, compounds of formula IV can be reacted with hydroxylamine in a suitable solvent mixture, such as THF/t-butanol/dichloromethane or water/dichloromethane, preferably at 0 °C, to give hydroxamic acids of formula II. Compounds of formula IV can generally be prepared, in a form directly useful for further reaction without isolation, by allowing carboxylic acids of formula 111 to react with thionyl chloride or oxalyl chloride, preferably in the presence of a catalytic amount of dimethylformamide, in dichoromethane solvent at -78 °C to room temperature.
Alternatively, the coupling reactions described above may be carried out with compounds of formula III (or IV) and O-protected derivatives of hydroxylamine, where
Pg is a protecting group, for example, benzyl, tert-butyl, t-butyldimethylsilyl, or t- butyldiphenylsilyl, to give compounds of formula V. Deprotection of compounds of formula V using conventional methods (for example, see "Protective Groups in Organic Synthesis", T.W. Greene and P. G. M. Wuts, Wiley-lnterscience 1991 ) can provide compounds of formula II.
Carboxylic acids III can be prepared as shown in Scheme 2 by reaction of α- amino acids with arylsulfonyl chlorides of formula VIII, under biphasic basic conditions as described, for example, in "The Chemistry of the Amino Acids", J.P. Greenstein and M. Winitz, Robert E. Krieger Publishing Company, 1984, p. 886-889.
Scheme 2
α-Amino acids are commercially-available, or can be prepared according to methods familiar to those skilled in the art. Carboxylic acids III can also prepared by reaction of α-amino acid derivatives where Pg is any suitable protecting group as described, for example, in "Protective Groups in Organic Synthesis", T.W. Greene and P. G. M. Wuts, Wiley-lnterscience 1991 , with aryl sulfonyl chlorides VIII to give sulfonamides VI under any of a variety of reaction conditions known to those skilled in the art for the sulfonylation of amines. Deprotection of VI to give the acids III can
be carried out as appropriate to the protecting group Pg. As is evident to those skilled in the art, manipulations of functionality in the amino acid side chain R or in the aryl group Ar may be readily effected at the stage of VI prior to the deprotection of VI to III. Amino acid derivatives VII, are commercially available, or are prepared according to methods familiar to those skilled in the art.
One variant of sequence shown in Scheme 2 that is particularly preferred in the context of the present invention is outlined in Scheme 3.
Scheme 3
Treatment of D-penicillamine with a molar equivalent of a trialkylchlorosilane, such as trimethylsiiyl chloride or dimethylthexylsilyl chloride, and a molar equivalent of a suitable base, such as 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or diisopropylethylamine, in suitable solvent, such as DMF, at approximately 25 °C for 1 to 6 hours can provide the silyl ester Vll-A. The identity of R4 is dependent upon the reactant used to obtain the silyl ester Vll-A, as is recognized by one skilled in the art. Without isolation, the solution of this ester Vll-A can be treated with an additional DBU (at least one molar equivalent) and an alkylating reagent R5-X, where R5 is an alkyl group, preferably a CH2-heteroaryl group, to give the S-alkylated silyl ester VII- B. Again without isolation, the resulting solution of Vll-B can be treated with the aryl sulfonyl chloride VIII to provide the sulfonamide silyl ester Vll-C. Upon work-up or, in the case of more stable silyl esters, brief treatment with acidic methanol, the silyl ester Vll-C undergoes hydrolysis to provide the desired acid lll-A.
Scheme 4
Aryl sulfonyl chlorides VIII are most readily available by chlorosulfonylation of the corresponding aryl phenyl ethers (IX, where Y = O) and aryl phenyl sulfides (IX where Y =S), as outlined in Scheme 4. In general, treatment of IX with a little over one molar equivalent of chlorosulfonic acid in a suitable inert solvent, such as 1 ,2- dichloroethane or dichloromethane, at -20 °C to 25 °C for a period of one to twenty- four hours can generate the corresponding sulfonic acid intermediate X. Without isolation, X is further converted to the sulfonyl chloride VIII by reaction with, for example, oxalyl chloride or thionyl chloride and cataltyic DMF. In some cases, excess chlorosulfonic acid is effective at converting IX directly to VIII via the intermediacy of X. Compounds of the formula IX are commercially-available, or may be readily prepared by those skilled in the art from commercially-available materials by the Ullman reaction.
Other compounds of the formula I may be prepared by methods known to those skilled in the art in a manner analagous to the general procedures described above. Specific examples of methods used to prepare the inventive compounds are described below along with illustrative preferred embodiments of the inventive compounds of the formula I, or their pharmaceutically acceptable prodrugs, salts or solvates.
The following specific examples are intended to be illustrative of the invention and should not be construed as limiting the scope of the invention as defined by the appended claims. These examples include preferred embodiments of the inventive compounds.
Examples Example 1. Preparation of Intermediate Compounds of formula Vlll-A.
Vlll-a
Example 1 (a) 4-Phenoxybenzenesulfonyl chloride {Vlll-A: Z=H}
To a stirred solution of 42.5 g (0.25 mol) of phenyl ether in 200 mL of dichloromethane at -20 °C under argon was slowly added 23.3 g (0.20 mol) of chlorosulfonic acid. After the addition was complete, the reaction was allowed to slowly warm to room temperature. After 16 hours, 150 mL of isooctane was added, and the solution was concentrated to an oily residue. Redissolution in 200 mL of 1 :3 dichloromethane/isooctane and reconcentration with cooling to about 100 mL gave a solid. The supernatant was decanted, and the solid was triturated with additional isooctane and then dried in vacuo to give 55.2 g of crude 4-phenoxybenzene sulfonic acid. The crude acid was dissolved in 200 mL of dichloromethane, and 22 mL (32 g,
0.25 mol) of oxalyl chloride was added, followed by 2.5 mL of N,N- dimethylformamide. After 2 days, the reaction solution was poured into 200 mL of ice water, and extracted with 400 mL of hexane. The organic layer was washed with
100 mL of water and 100 mL of brine, dried over magnesium sulfate, and concentrated. Recrystallization of the residue from dichloromethane/isooctane gave
1 38.5 g of 4-phenoxybenzenesulfonyl chloride as a white solid: mp 41.5 °C; H-NMR
(CDCI3) δ 7.10 (apparent t, 4 H, J = 7 Hz), 7.28 (t, 1 H, J = 7 Hz), 7.46 (t, 2H, J = 8
Hz), 7.98 (d, 2H, J = 8.8 Hz).
Example 1(b) 4-(4-Methylphenoxy)benzenesulfonyl chloride {Vlll-A: Z=CH3}
To a solution of 1.84 g (10.0 mmol) of 4-methyldiphenyl ether (J. Chem. Soc, Perkin Trans. . ; 1992, 407-408) with 2 mL of dichloromethane in an ice-bath was added a solution of chlorosulfonic acid ( 0.73mL, 11.0 mmol) in 2 mL of dichloromethane dropwise. The resulting mixture was stirred at 0°C to room temperature for 2 hours, and then oxalyl chloride (11.14mL, 13.0 mmol) was added dropwise, followed by 0.15 mL of DMF. The resulting mixture was heated to 40°C for
1 hour and then allowed to cool to room tempereature over a 2 hour period. The reaction mixture was poured into ice-pH 7 phosphate buffer (50mL), then extracted with EtOAc:Hexane (4:3) (3x150mL). The combined organic layers were washed with brine (75mL). The aqueous layer was extracted with EtOAc/Hexane(4:3) (150mL).
The organic layer was dried over Na2S04 then evaporated by vacuum to give crude product as white solid. This solid was triturated with hexane and collected by filtration, then dried under high vacuum to give 1.555 g (57%) of 4-(4-
1 methylphenoxy)benzenesulfonyl chloride as white solid: mp 295-300°C. H-NMR
(DMSO-d6) δ 2.34 (s, 3H), 6.91-6.99 (dd, J = 7.7,8.4Hz, 4H), 7.24-7.27 (d, J = 8.4Hz,
2H), 7.61-7.63 (d, J = 8.1 Hz, 2H).
Anal. calc. for
C, 55.22; H, 3.92; S, 11.34; Cl, 12.71. Found: C, 55.06;
H, 3.95; S, 1 1.28; Cl, 12.71.
Prepared in a similar fashion were the following:
Example 1(b) 4-(4-Bromophenoxy)benzenesulfonyl chloride {Vlll-A: Z=Br}: from
4-bromobiphenyl ether (supplier: Aldrich), mp 81 °C.
Example 1(c) 4-(4-Chlorophenoxy)benzenesulfonyl chloride {Vlll-A: Z=CI}: from
4-chlorobiphenyl ether (supplier: Transworld), mp 61 °C
Example 1(d) 4-(4-Fluorophenoxy)benzenesulfonyi chloride {Vlll-A: Z=F}: from
4-fluorobiphenyl ether (supplier: Riedel-de Haen), mp 76 °C
Example 1(e) 4-(4-lodophenoxy)benzenesulfonyl chloride {Vlll-A: Z=l} from 4- iodobiphenyl ether (supplier: Transworld): mp 85-88 °C.
Example 1(f) 4-(4-Cyanophenoxy)benzenesulfonyl chloride {Vlll-A: Z=CN}: from
4-cyanobiphenyl ether (supplier: Transworld): mp 98-102 °C
Example 1(g) 4-(4-Trifluoromethyphenoxy)benzenesulfony! chloride {Vlll-A:
Z=CF3>: from 4-trifiuoromethylbiphenyl ether (J.Chem.Soc.Perkin Trans.1 1988, 3229-
3232): mp 265-270°C; 1H-NMR (CDCI3) δ 7.04 (d, J = 8.4Hz, 2H), 7.14 (d, J = 8.7Hz,
2H), 7.65 (d, J = 8.8Hz, 2H), 7.73 (d, J = 8.7Hz, 2H)\
Anal. calc. for C13H803SF3CI (336.71 ): C, 46.34; H, 2.39; S, 9.52. Found: C, 46.34; H,
2.49; S, 9.37.
Example 1(h) 4-(Pyrid-2-yl)oxybenzenesulfonyl chloride
From 2-phenoxypyridine (supplier: ICN): 1H NMR (CDCI3) d 8.25 (m, 1 H),
8.05 (d, 2H, J = 9 Hz), 7.81 (t, 1 H, J = 8 Hz), 7.34 (d, 2H, J = 9 Hz), 7.15 (dd, 1 H, J
7.6 5 Hz), 7.06 (d, 1 H, J = 8 Hz).
Example 2. Preparation of Intermediates of Formula VIII.
Example 2(a) 4-(Pyrid-4-yl)oxybenzenesulfonyl chloride hydrochloride
To a suspension of 4-(pyrid-4-yl)oxybenzenesulfonic acid (1.3 kg) in acetonitrile (8 L), was added N,N-dimethylformamide (12.35 mL), and the viscous reaction mixture was heated to 75 °C. Thionyl chloride (756 mL) was added to the reaction mixture over 30 minutes. The reaction mixture slowly became less viscous and became homogeneous after 45 minutes, which indicated the reaction was complete. A portion of the solvent (4 L) was evaporated under vacuum and tert-butyl methyl ether (4 L) was added. The resulting slurry was filtered under inert atmosphere. The filter cake was rinsed with tert-butyl methyl ether (2 L) and the solid dried under vacuum to yield 4-(pyrid-4-yl)oxybenzenesulfonyl chloride hydrochloride (1.35 kg) as a hygroscopic.off-white solid of peariescent flakes: mp 182 °C; 1H NMR (CDCI3): δ 8.87 (d, J = 7 Hz, 2H), 8.24 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 7 Hz, 2H). The starting material was prepared as follows:
To a vigorously stirred solution of 1.00 kg (5.85 mol) of 4-phenoxypyridine (Tetrahedron, 1978, 34, 2069-2076) in dry 1 ,2-dichloroethane (3000 L) at -10°C under a stream of argon was added chlorosulfonic acid (974 mL) at a rate so as to maintain the reaction temperature below 0°C. After half of the chlorosulfonic acid was added, the exotherm stopped. The cooling bath was removed and the addition of chlorosulfonic acid continued over 3 hours while the reaction solution warmed to
room temperature. While continually purging with argon, the vigorously stirred reaction mixture was heated to 45°C. After 20 hours, the reaction mixture was cooled to room temperature and slowly poured into vigorously stirred ice cold water (5 L). Potassium phosphate tribasic (212 g) was added as a solid to the mixture and this was stirred for 10 minutes followed by addition of sodium hydroxide (2M) to pH 2. After stirring for 1 hour, the pH was changed to 7 by the addition of sodium hydroxide (2M). Agitation was continued for 5 minutes; then the organic layer was drained off and discarded. The mixture was extracted a second time with dichloromethane (2 L), and the organic layer drained off and discarded. The remaining aqueous phase was extracted with tetrabutylammonium bromide (940 g) in dichloromethane (6L), adjusting the aqueous phase to pH 7 with 2M aq. sodium hydroxide as necessary. The extraction was repeated two more times and the combined organic layers were dried over magnesium sulfate, filtered, and concentrated. The residue was dissolved with 20% ethanol in ethyl acetate (8 L, dry), and hydrogen chloride gas added to achieve a pH of 1. The solid was filtered off, and the filter cake was rinsed with the precipitation solvent mixture (20% ethyanol in ethyl acetate, 2 L). The solid was dried under vacuum at 45°C for 15 hours to yield 4-(pyrid-4-yl)oxybenzenesulfonic acid (1.3 kg) as a white powdery solid. mp dec. >275 °C; 1H NMR (DMSO-d6): δ 8.86 (dd, J = 1.5, 7.4 Hz, 2H), 7.84 (dd, J = 1.5, 7 Hz, 2H), 7.54 (dd, J = 1.5, 7.4 Hz, 2H), 7.35 (dd, J = 1.5, 7 Hz, 2H). Anal. calc. for
C, 52.58; H, 3.61 ; N, 5.57; S, 12.76. Found: C, 52.50; H, 3.69; N, 5.51 ; S, 12.67. Example 2(b). 4-(Pyrid-4-yl)sulfanylbenzenesulfonyl chloride hydrochloride
Prepared as in Example 2(a) from 4-(phenylsulfanyl)pyridine (prepared as in J. Am. Chem. Soc. 1937, 59, 2697): mp 194°C.
1H NMR (CDCI3) δ 8.61 (d, J = 7 Hz, 2H), 8.25-8.20 (m, 2H), 7.93-7.8(m, 2H), 7.48 (d, J = 7 Hz).
Example 3. Preparation of Compounds of Formula lll-A
Example 3(a). S-[(1 -Benzyl-1 H-imidazol-2-yl)methyl]-N-[4-(4-fluorophenoxy) benzenesulfonyl]-D-penicillamine {lll-A, W=(1 -BenzyI-1 H-imidazol-2-yl)CH2S, Z=F}
To a suspension of D-penicillamine (0.500 g, 3.35 mmol) in DMF (7 mL) was added diisopropylethylamine (0.70 mL., 4.0 mmol), followed by dimethylthexylsilyl chloride (0.725 mL, 3.68 mmol). After 2.5 hours at room temperature, the solution was cooled to 0 °C, and DBU (1.59 mL, 10.7 mmol) was added, followed by 2- chloromethyl-1-benzyl-1 H-imidazole hydrochloride (0.977g., 4.02 mmol, Maybridge). The solution was allowed to warm to room temperature. After 3 hours, the solution was recooled to 0 °C, diisopropylethylamine (0.70 mL., 4.0 mmol) was added, followed by 4-(4-fluorophenoxy)benzenesulfonyl chloride (1.01 g., 4.00 mmol). The solution was allowed to slowly warm to room temperature, stirred for 5 h, and then partitioned between brine and ethyl acetate. The organic layer was washed with brine, filtered through celite, and concentrated. The residue was dissolved in methanol (50 mL), and treated with acetic acid (0.400 mL). After 2 hours at room temperature, the solution was concentrated, and the residue was purified on silica, eluting with 5% methanol/dichloromethane. Trituration of the residue with 25% diethyl ether/hexane gave S-[(1-benzyl-1 H-imidazol-2-yl)methyl]-N-[4-(4- fluorophenoxy)benzenesulfonyl]-D-penicillamine as a white solid in 52% yield: mp 172-173 °C; 1H-NMR (CDCI3) δ 1.29 (s, 3H), 1.44 (s, 3H), 3.75-4.02 (m, 3H), 5.29 (s, 2H), 6.95-7.65 (m, 15H).
Anal calcd. for C28H28FN305S2: C, 59.03; H, 4.95; N, 7.38; S, 11.26. Found: C, 58.77; H, 4.97; N, 7.33; S, 11.07.
Prepared in a similar manner were Examples 3(b) to 3 (n): Example 3(b). N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(1 -benzyl-1 H- imidazol-2-yl)methyl]-D-penicillamine {lll-A, W = (1-Benzyl-1 H-«midazol-2- yl)CH2S, Z = Br}. mp 176-177 °C; H-NMR (CD3OD) δ 1.36 & 1.41 (2s, 6H), 3.67 (s, 1 H), 4.00 (m, 2H),
5.36 (s, 2H), 7.01-7.85 (m, 15H); FAB HRMS: expected (M+Cs)=761.9708. Found
(M+Cs)=761.9728
Anal calcd. for C28H28BrN305S2: C, 53.33; H, 4.48; N, 6.66; S, 10.17. Found: C,
53.25; H, 4.43; N, 6.59; S, 10.06.
Example 3(c). N-[4-(4-Fluorophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = F} mp 194 °C; 1 H-NMR (DMSO-d6) δ 1.33 (s, 6H), 3.85-3.97 (m, 3H), 7.12 (d, J = 9 Hz,
2H), 7.18-7.54 (m, 6H), 7.70-7.79 ( m, 1 H), 7.84 (d, J = 9 Hz, 2H), 8.3 (d, J = 10 Hz, 1 H),
8.4 (d, J = 4 Hz, 1 H), 12.68 (br s, 1 H).
Anal. calc. for C23H23FN205S2: C, 56.31 ; H, 4.73; N, 5.71. Found: C, 56.06; H, 4.78;
N, 5.64.
Example 3(d). N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = Br} mp 165-168 °C; 1H-NMR (CD3OD) δ 1.39 (s, 3H), 1.45 (s,3), 3.92-3.99 (m, 2H), 7.03-
7.12 (dd, J = 9 & 2 Hz, 4H), 7.24-7.26 (m, 1 H), 7.53-7.60 (m, 3H), 7.82-7.90 (m, 3H),
8.52 (d, J = 3 Hz, 1 H).
Anal. calc. for C23H24N3O5S2F»0.2 H20: C, 49.77; H, 4.25; N, 5.05. Found: C, 49.93;
H, 4.19; N, 4.12.
Example 3(e). N-[4-(4-Fluorophenoxy)benzenesulfonyl]-S-[(pyrid-3-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-3-yl)CH2S, Z = F}. mp 200-201 °C; 1 H-NMR (DMSO-d6) δ 1.35 (s, 6H), 3.87 (m,3H), 7.11-8.60 (m, 12H),
8.25 (br s, 1 H).
Anal. calc. for C23H23FN2O5S2«0.3 H20: C, 55.49; H, 4.82; N, 5.63. Found: C,55.34;
H. 4.67; N. 5.6.
Example 3(f). N-[4-(4-Fluorophenoxy)benzenesulfonyl]-S-[(pyrid-4-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-4-yl)CH2S, Z = F}. mp 197°C; Η-NMR (DMSO-d6) δ 1.34 (s, 6H), 3.80-4.00 (m, 3H), 7.00-8.80 (m, 13H).
8.25 (s, 1 H).
Anal. calc. for C23H23FN2O5S2*0.1 H2O: C, 56.11 ; H, 4.75; N, 5.69. Found: C, 55.78;
H, 4.75; N, 5.73.
Example 3(g). N-[4-(4-Methylphenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = Me} mp 185-187°C; H-NMR (CD3OD) δ 1.39 (s, 3H) 1.44 (s, 3H), 2.39 (s, 3H), 3.92-4.01
(m, 3H), 6.98-7.04 (m, 4H), 7.25-7.28 (m, 3H), 7.54 (d, J = 7 Hz, 2H), 7.82-7.85 (m, 3H),
8.42 (d, J = 6 Hz, 1 H).
Anal. calc. for C24H26N2O5S2*0.35 CH2CI2: C, 56.64; H, 5.21 ; N, 5.43. Found:
C, 56.48; H, 5.32; N, 5.67.
Example 3(h). N-[4-(4-Cyanophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = CN} mp 170-173X; Η-NMR (CD3OD) δ_1.42 (s, 3H), 1.44 (s, 3H), 3.82- 4.01 (m, 3H),
7.19-7.23 (m, 5H), 7.60 (d, J = 5 Hz, 1 H), 7.79 (d, J = 4 Hz, 3H), 7.95-7.98 (d, J = 9
Hz, 2H) 8.42-8.43 (d, J = 5 Hz,1 H).
Anal. calc. for C24H23N3O5S2.0.7H2O»0.6CH2CI2: c> 52.23; H, 4.82; N, 7.28
Found: C, 52.22; H, 4.87; N, 7.38.
Example 3(i). N-[4-(4-lodophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = I} mp 177-180°C; 1H-NMR (CD3OD) δ 1.40 (s, 3H), 1.44 (s, 3H), 3.87-4.01 (m, 3H),
6.91 (d, J = 8 Hz, 2H), 7.10 (d, J = 9 Hz, J = 2H), 7.32-7.56 (m, 1 H), 7.77 (d, J = 8
Hz, 1 H), 7.81-7.89 (m, 4H), 8.44 (d, J = 5 Hz, 2H).
Anal. calc. for C23H23N2O5S2l*0.1 H2O : C, 46.15; H, 3.94; N, 4.65. Found: C,
46.15; H, 3.95; N, 4.51.
Example 3(j). N-[4-(4-(trifluoromethyl)phenoxy)benzenesulfonyl]-S-[(pyrid-2- yl)methyl]-D-penicillamine {lll-A, W = (pyrid-2-yl)CH2S, Z = CF3} mp 182-185°C; 1H-NMR (CD3OD) δ 1.36 (s, 3H),1.41 (s, 3H), 3.83-3.98 (m, 3H),
7.14-7.30 (m, 4H), 7.51 (d, J = 8 Hz, 2H), 7.69-7.91 (m, 4H), 8.41 (d, J = 4 Hz, 2H).
Anal. calc. for C24H23N2O5S2F3«0.35 hexane: C, 54.92; H, 4.93; N, 4.91.
Found: C, 55.07; H, 5.01 ; N, 5.06.
Example 3(k). N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(5-methylisoxazol-3- yl)methyl]-D-penicillamine {lll-A, W = (5-methylisoxazol-3-yl)CH2S, Z = Br} mp 119 °C; 1H-NMR (DMSO-d6) δ 1.35 (s, 6H), 2.4 (s, 3H), 3.3 (br s,1 H), 3.73 (d, J
= 14 Hz, 1 H), 3.79 (d, J = 14 Hz, 1 H), 6.21 (s, 1 H), 7.1-7.2 ( br s, 1 H), 7.13 (d, J = 9
Hz, 2H), 7.15 (d, J = 9 Hz, 2H), 7.68 (d, J = 9 Hz, 2 H), 7.82 (d, J = 9 Hz, 2H).
Anal. calc. for C22H23BrN2O6S2*0.1 H2O*0.3 CHCI3: C, 45.16; H, 3.99; N, 4.72.
Found: C, 45.24; H, 4.03; N, 4.7.
Example 3(1). N-[4-(4-Fluorophenoxy)benzenesulfonyl]-S-[(5-methylisoxazol-3- yl)methyl]-D-penicillamine {lll-A, W = (5-methylisoxazol-3-yl)CH2S, Z = F} mp 112-113 °C; Η-NMR (DMSO-d6) δ 1.35 (s, 6H), 2.40 (s, 3H), 3.3-3.97 (br s,1 H),
3.73 (d, J = 13 Hz, 1 H), 3.79 (d, J = 13 Hz, 1 H), 6.24 (s, 1 H), 6.9-7.2 (br s, 1 H), 7.07
(d, J = 9 Hz, 2H), 7.2-7.38 (m, 4H), 7.8 (d, J = 9 Hz, 2H).
Anal. calc. for C22H23FN2O6S2«0.1 H2O«0.3 CHCI3: C, 50.33; H, 4.45; N, 5.26.
Found: C, 50.27; H, 4.35; N, 5.3.
Example 3(m). S-Benzyl-N-[4-phenoxybenzenesulfonyl]-D-penicillamine {lll-A,
W = PhCH2S, Z = H} mp 92-95 °C; 1H-NMR (CDCI3) δ 1.36 (s, 3H), 1.59 (s, 3H), 2.25 (br s, 1 H), 5.46
(d, J = 10 Hz, 2H), 6.99-7.39 (m, 7H), 7.61-7.85 (m, 7H).
Anal. calc. for C24H26NO5S2«0.8 NH3: C, 59.32; H, 5.89; N, 5.13. Found: C, 59.58;
H, 5.92; N, 5.13.
Example 3(n). S-(t-Butoxycarbonyl)methyl-N-[4-(4-fluorophenoxy)benzene- sulfonyl]-D-penicillamine {lll-A, W = t-BuO2CCH2S, Z = F} mp 75 °C; 1H-NMR (CDCI3) δ 1.26 (s, 3H), 1.34 (s, 3H), 1.43 (s, 9H), 3.16 (d, J =
15 Hz, 1 H), 3.26 (d, J = 15 Hz, 1 H), 3.76 (d, J = 8 Hz, 1 H), 6.5 (br s, 1 H), 6.94 (d,
J = 9 Hz, 2H), 6.97-7.1 (m, 4H), 7.82 (d, J = 9 Hz, 2H).
Anal. calc. for C23H28FNO7S2«0.2CHCI3: C, 51.84; H, 5.29; N, 2.61. Found; C,
51.79; H, 5.26; N, 2.70.
Example 3(o). N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[1 -methyl-1 H- imidazol-2-yl)methyl]-D-penicillamine {lll-A, W = (1 -methyl-1 H-imidazol-2- yl)CH2S, Z = Br}: 1H NMR (DMSO): δ 1.20 (s, 3H), 1.27 (s, 3H), 3.61 (s, 3H),
3.79 (s, 1 H), 3.93 (s, 2H), 6.81 (s, 1 H), 7.06-7.14(m, 5H), 7.62 (d, 2H, J = 9.0 Hz),
7.70 (d, 2H, J = 9.0 Hz); ESIMS Calcd for C22H2405N3S2Br: 554/556. Found:
554/556.
Anal. Calcd for C22H2405N3S2 • 0.08 HOAc: C, 45.59; H, 4.38; N, 7.51 ; S, 11.47;
Br, 14.29.
Found: C, 45.55; H, 4.37; N, 7.37; S, 11.46, Br, 14.34
Example 3(p). N-[4-(4-Chlorophenoxy)benzenesulfonyl]-D-tert-leucine {lll-A,
W = CH3, Z = Cl}.
To a suspension of D-tert-leucine (0.250 g., 1.91 mmol, Aldrich) in dichloromethane (3 mL) and DMF (1.5 mL) was added N-methylmorpholine (0.50 mL., 4.55 mmol), followed by chlorotrimethylsilane (0.30 mL., 2.36 mmol) and the mixture stirred at room temperature for 6 hours. Diisopropylethylamine (0.300 mL., 1.72 mmol) was added, followed by 4-(4-chlorophenoxy)benzenesulfonyl chloride (0.636g., 2.10 mmol, from example 1 (c)) portionwise via a solid addition funnel. The resulting solution was then stirred at room temperature for 3.5 hours, and then partitioned between ethyl acetate and 1 N aq. sodium bisulfate. The organic layer was washed with brine, dried over MgS04, and concentrated. The residue was purified on silica gel, eluting with 40% ethyl acetate in hexane followed by 10% methanol in dichloromethane, to give N-[4-(4- chlorophenoxy)benzenesulfonyl]-D-tert-leucine as a white solid in 62% yield: mp
138-140 °C; 1H-NMR (CDCI3) δ 0.949 (s, 9H), 3.51-3.54 (d, 1 H, J = 10.3 Hz),
5.55-5.59 (m, 1 H), 6.94-7.83 (m, 8H).
FAB HRMS: expected(M+H)=398.0829, found(M+H)=398.0840
Examples 3(q), 3(r), and 3(s) were prepared following the procedure provided in
Example 3(p):
Example 3(q). N-[4-(4-Fluorophenoxy)benzenesulfonyl]-D-tert-leucine {lll-A,
W = CH3, Z = F}. mp 170-174 °C.
Example 3(r). N-[4-Phenoxybenzenesulfonyl]-D-tert-leucine {lll-A, W = CH3, Z =
H} mp 147-150°C; 1H-NMR (CDCI3) δ 0.98 (s, 9H), 3.59 (d, J = 10.7Hz, 1 H), 5.17 (d, J = 10.5Hz, 1 H), 6.99-7.43 (m, 6H), 7.77 ( d, J = 7.0Hz, 3H).
Anal. calc. for C18H21NO5S«0.3 H20 (368.82): C, 58.61 ; H, 5.90; N, 3.80.
Found: C, 58.72; H, 5.90; N, 3.74.
Example 3(s). N-[4-(4-Bromophenoxy)benzenesulfonyl]-D-(β-hydroxy)valine
{lll-A, W = OH, Z = Br}
Starting from D-3-hydroxyvaline, which was prepared by the method described in
J. Org. Chem. 1996, 61 , 2582-2583; mp 153-4oC. 1H NMR (DMSO-d6): d 0.88 (s,
3H), 1.07 (s, 3H), 2.80 (d, 1 H, J = 6.0 Hz), 6.79 (d, 1 H, J = 6.0 Hz), 7.06 - 7.11 (m,
4H), 7.62 (d, 2H, J = 9.0 Hz), 7.76 (d, 2H, J = 8.1 Hz); ESIMS Calcd for
C17H1806NSBr: 444/446. Found: 444/446.
Anal. Calcd for C17H18BrN06S: C, 45.96; H, 4.08; N, 3.15; S, 7.22; Br, 17.98.
Found: C, 45.73; H, 4.05; N, 3.08; S, 7.08, Br, 17.91.
In a similar fashion may be prepared:
Example 3(t). N-[4-(4-Bromophenoxy)benzenesulfonyl]-D-tert-leucine {lll-A, W
= CH3, Z = Br}
Example 3(u). N-[4-(4-Chlorophenoxy)benzenesulfonyl]-D-(β-hydroxy)vaIine
{lll-A, W = OH, Z = Cl}
Example 3(v). N-[4-(4-Chlorophenoxy)benzenesulfonyl]-D-valine {lll-A, W = H,
Z = CI}
Example 4. Preparation of Compounds of Formula III.
Prepared in a similar manner as in Example 3(a) were Examples 4(a), 4(b) and
4(c).
Example 4(a). S-Benzyl-N-[4-(pyrid-4-yl)oxybenzenesulfonyl]-D-penicillamine
mp 105-110
3.39-3.85 (m, 2H), 7.07 (d, J = 6 Hz, 2H), 7.34-7.39 (m, 4H), 7.95 (d, J = 8 Hz, 3H), 8.41 (d, J = 9 Hz, 2H), 8.58 (d, J = 6 Hz, 2H).
Anal. calc. for C23H24N205S2: C, 58.45; H, 5.12; N, 5.93. Found: C, 58.36; H, 5.16; N, 5.89
Example 4(b). S-[(5-Methylisoxazol-3-yl)methyl]-N-[4(pyrid-4-yl)oxybenzene- sulfony!]-D-penicillamine.
mp 90-92 °C. 1H NMR (CDCI3): δ 1.42 (s, 3H), 1.46 (s, 3H), 2.40 (s, 3H), 3.80 (dd, 3H, J = 14.3, 19.3 Hz), 5.75 (d, 1 H, J = 10.2 Hz), 6.02 (s, 1 H), 6.82 (d, 2H, J = 6.5 Hz), 7.08 (d, 2H, J = 8.7 Hz), 7.98 (d, 2H, J = 8.7 Hz), 8.40 (d, 2H, J = 6.5 Hz); FAB HRMS Calcd for C21H2406N3S2: 478.1107. Found: 478.1117. Anal. Calcd for C21H2306N3S2*1.5 H20: C, 49.99; H, 5.19; N, 8.33; S, 12.71. Found: C, 49.57; H, 4.94; N, 8.15; S, 12.43. Example 4(c). S-[(5-Methylisoxazol-3-yi)methyl]-N-[4(pyrid-4-yl) sulfanylbenzenesuifonyl]-D-penicillamine.
mp 79-85 °C. 1H NMR (DMSO-d6) δ 1.27 (s, 3H), 1.29 (s, 3H), 2.33 (s, 2H), 3.73 (dd, 2H, J = 1.6, 12.6 Hz), 3.77-3.83 (m, 1 H), 6.14 (d, 1 H, J = 1.6 Hz), 7.13 (dd, 1 H, J = 1.6, 4.7 Hz), 7.68 (d, 2H, J = 8.7 Hz), 7.85 (d, 2H, J = 8.7 Hz), 8.32-8.47 (m, 3H). IR (KBr): 3425, 3248, 1713, 1608, 1557, 1478, 1337, 1161 , 1096, 1077, 756, 620 cm"1. HR FABMS Calcd for C21H24N305S3 (M+H): 494.0878. Found: 494.0890.
Anal. Calcd for C21H23N305S3 #0.1 C7H16 • 0.3 CHCI3: C, 48.98; H, 4.65; N, 7.79; S, 17.83. Found: C, 48.77; H, 4.69; N, 7.63; S, 17.76. Prepared in a manner similar to Example 3(p) was Example 4(d).
Example 4(d). N-[4-(Pyrid-2-yl)oxy)benzenesulfonyl]-D-tert-leucine.
mp 202 °C (decomp); 1H-NMR (CDCI3) δ 1.02 (s, 9H), 3.55 (d, 1 H, J = 10 Hz),
5.30 (d, 1 H, J = 10 Hz), 7.05-8.21 (m, 8H); FAB HRMS: Expected ( M+Cs)+ =
497.0147. Found (M+Cs)+ = 497.0160.
Example 4 (e). N-[4-(4-(Furan-3-yl)phenoxy)benzenesulfonyl]-S-[(pyrid-2- yl)methyl]-D-penicillamine.
To a suspension of 221 mg (0.40 mmol) of N-[4-(4-bromophenoxy) benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D-penicillamine (from example 3(d)) in 2 mL of benzene and 2 mL of 2M aqueous Na2C03 solution was added a solution of 71 mg (0.48 mmol) of 3-furan boronic acid (J. Org. Chem. 1984, 49, 5237-5243) in 2 mL of EtOH. To the resulting mixture was added solid Pd(PPh3)4 (46mg, 0.04 mmol) under a flow of Ar. The mixture was heated at 80°C with vigorous stirring for 72 hours, cooled to room temperature, and partitioned between ehtyl acetate and AcOH/H20 buffer (pH 3). The aqueous layer was adjusted to pH of 3 by adding AcOH, then extracted with EtOAc (2x70mL). The combined organic layers were washed with brine, dried over Na2S04,and concentrated. The residual yellow solid was chromatographed on silica gel, eluting first with CH2CI2 then with 10% methanol in dichloromethane to elute the product fractions. After concentration of the product-containing fractions, the residue was triturated with hexane/t-butyl methyl ether, and the solid was collected by filtration. The solid was dried in high vacuum to give 166.1 mg (77%) of N-[4-(4-(furan-3-yl)phenoxy)benzenesulfonyi]-
1 S-[(pyrid-2-yl)methyl]-D-penicillamine as a yellow solid: mp 185-189°C; H-NMR
(CDCI3) δ 1.40 (s, 3H) 1.44 (s, 3H), 3.32-4.01 (m, 3H), 6.83 (s, 1 H), 7.10-7.13 (m,
4H), 7.22-7.23 (m, 2H), 7.57-7.92 (m, 8H), 8.42 (d, J = 4 Hz, 2H).
Anal. calc. for C27H26N206S2: C, 60.20; H, 4.87; N, 5.20. Found: C, 60.00; H, 4.88;
N. 4.94.
Example 5. S-Carboxymethyl-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D- penicillamine
To a solution of S-(t-Butoxycar bonyl)methyl-N-[4-(4- fluorophenoxy)benzenesulfonyl]-D-penicillamine (188.8 mg, 0.367 mmol) in 3.4 mL of dichloromethane at 20 °C was added trifluoroacetic acid (0.85 mL). The solution was stirred for 16 h and concentrated in vacuo. The residue was partitioned between ethyl acetate (25 mL) and 1 M aq. phosphate buffer (pH 7).
The aqueous layer was extracted with two additional portions of ethyl acetate (25 mL), and the combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The residue was triturated with diethyl ether (5 mL) to give 67 mg (40%) of S-Carboxymethyl-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D-
1 penicillamine as an off-white solid: mp 69 °C; H-NMR (DMSO-d6) δ 1.32 (br s,
6H), 3.25-3.5 (br m, 3H), 7.12 (d, J = 8 Hz, 2H), 7.2-7.5 (m, 4H), 7.82 (d, J = 8 Hz,
2H), 8.00-8.40 (br s, 1 H), 12.5-13.2 (v br s, 1 H).
Anal. calc. for C19H20FNO7S2«0.7 H20* 0.2 Et20: C, 49.04; H, 4.86; N, 2.89.
Found: C, 49.04; H, 4.91 ; N, 2.78.
Example 6: Preparation of Compounds of Formula III.
Example 6(a) S-Methyl-N-[4-(phenoxy)benzenesulfonyl]-D-penicillamine {III-
A, W = CH3S, Z = H}
To a solution of S-methyl-N-[4-(phenoxy)benzenesulfonyl]-D-penicillamine methyl ester (0.250g., 0.610 mmol) in DMSO (3 mL) at room temperature was
added sodium thiomethoxide (171 mg., 2.44 mmol) in one portion. The solution was heated at 45 °C for18 hours, and then cooled to 0 °C and acidified to pH=5 using 1 N aqueous sodium bisulfate. The mixture was partitioned between ethyl acetate and water, and the organic phase was washed with brine, dried over MgS04, and concentrated. The residue was purified on silica eluting with 8 to 12% methanoi in dichloromethane to give S-methyl-N-[4-(phenoxy)benzenesulfonyi]-D- penicillamine as a white solid in 95 % yield: mp 156-158 °C; 1H-NMR (DMSO-d6) δ 1.28 (s, 3H), 1.31 (s, 3H), 1.97 (s,3H), 7.08-7.82 (m, 10H). Anal. calc. for C18H21NO5S2*0.5 CH2CI2: C, 50.73; H, 5.06; N, 3.20. Found: C, 50.46; H, 5.00; N, 3.24. The starting material was prepared as follows: (/ ) S-Methyl-D-penicillamine methyl ester
To a 0 °C solution of D-penicillamine methyl ester hydrochloride (0.250g., 1.25 mmoles) in DMF (4 mL) was added DBU (0.382 ml., 2.56 mmoles), followed by methyl iodide (0.081 ml., 1.31 mmoles). After 1 hour, the solution was partitioned between brine and ethyl acetate, and the organic layer was dried over sodium sulfate and concentrated. The residue was purified on silica, eluting with 6% methanoi in dichloromethane to give S-methyl-D-penicillamine methyl ester as a colorless oil in 81 % yield: 1H-NMR (CDC13) δ 1.25 (s, 3H) 1.35 (s, 3H), 2.02 (s, 3H), 3.44 (s,1 H), 3.72 (s, 3H); FAB HRMS:expected(M+H)=178.0902, found(M+H)=178.0905. (ii) S-Methyl-N-[4-(phenoxy)benzenesulfonyl]-D-penicillamine methyl ester
To a solution of S-methyl-D-penicillamine methyl ester (0.160g., 0.904 mmol) and diisopropylethylamine (0.172 mL, 0.99 mmol) in dichloromethane (3 mL) was added 4-phenoxybenzenesulfonyl chloride (0.304 g, 1.13 mmol) via solid addition funnel. After 2.5 hours at room temperature, the solution was concentrated and the residue was purified on silica, eluting with 20% ethyl acetate in hexane, to give S-methyl-N-[4-(phenoxy)benzenesulfonyl]-D-penicillamine methyl ester as a white solid in 87 % yield: H NMR (CDCI3) δ 1.31 (s, 3H), 1.37 (s, 3H), 1.96 (s,3H), 3.48 (s, 3H), 3.79 (d, 1 H, J=9 Hz), 5.34 (d, 1 H, J=10 Hz), 6.99-7.79 (m, 9H); FAB HRMS: expected (M+Na)=432.0915, found(M+Na)=432.0907.
Prepared in a similar manner was the following:
Example 6(b). S-Methyl-N-[4-(4-chlorophenoxy)benzenesulfonyl]-D- penicillamine {lll-A, W = CH3S, Z = Cl} mp 203 °C (decomp); 1H NMR (CDCI3) d 1.21 (s, 3H), 1.25 (s, 3H), 1.88 (s, 3H), 3.75-3.84 (m, 1 H), 6.91-7.95 (m, 9H); FAB HRMS: expected (M+Cs)+ = 561.9526. Found (M+Cs)+ = 561.9538.
Example 7 S-[2-(Methoxycarbonyl)ethyl]-N-[4-(4-fluorophenoxy)benzene- sulfonyl]-D-penicillamine {lll-A, W = EtO2C(CH2)2S, Z = F}
To a 0 °C solution of N-[4-(4-fluorophenoxy)benzenesulfonyl]-S-[2- (methoxycarbonyl)ethyl]-D-penicillamine allyl ester (0.36 g, 0.687 mmol) in 5 mL of ethyl acetate was added N-methylaniline followed by Pd(PPh3)4 (16 mg, 0.014 mmol). After 3 hours, the solution was concentrated, and the residue was purified by chromatography on silica gel, eluting first with 1 :1 ethyl acetate:hexane and then with 10% methanoi in dichloromethane to give N-[4-(4- fluorophenoxy)benzenesulfonyl]-S-[2-(methoxycarbonyl)ethyl]-D-penicillamine as a white solid in 89% yield: mp 123-124 °C; 1H-NMR(CDCI3) δ 1.27 (s, 3H), 1.35 (s, 3H), 2.40-2.82 (m, 4H), 3.71 (s, 3H), 3.94 (d, 1 H, J = 11 Hz), 5.60 (d, 1 H, J = 11 Hz), 6.93-7.82 (m, 8H); FAB HRMS: expected (M+Cs) = 618.0033. Found(M+Cs)=618.0038 The starting material was prepared as follows:
(i) N-(tert-Butoxycarbonyl)-S-[2-(methoxycarbonyl)ethyl]-D-penicillamine allyl ester
To a suspension of D-penicillamine (10.0 g., 67.02 mmol) in methanoi (100 mL) at 0 °C was added 14.5 mL (67 mmol) of a 25 wt% solution of sodium in methanoi dropwise. After 15 minutes, methyl acrylate (6.35 mL, 70 mmol) was added dropwise, and the solution was allowed to warm to room temperature overnight. Removal of the solvent by rotary evaporation provided a white solid, which was dissolved in 50% aqueous (100 mL). To the resulting solution was added triethylamine (14 mL, 100 mmol), followed by di-t-butyldicarbonate (16.05 g., 73.6 mmol). After stirring for 12 hours at room temperature, the mixture was concentrated to remove most of the THF, and the resulting aqueous solution was acidified with acetic acid and then extracted with ethyl acetate. The organic layer
was washed with brine, dried over magnesium sulfate, and concentrated. The residue was dissolved in THF (75 mL) and DBU (10.2 mL, 68.2 mmol) added, followed by addition of allyl bromide (6.14 mL, 71.0 mmol). The solution was stirred at room temperature for 5 hours, and then the solvent was removed by concentration under reduced pressure. The residue was purified on silica gel, eluting with 5% to 10% to 20% ethyl acetate in hexane, to provide N-(tert- butoxycarbonyl)-S-[2-(methoxycarbonyl)ethyl]-D-penicillamine allyl ester as a colorless oil in 44% overall yield: 1H-NMR (CDCI3) δ 1.36 (s, 3H), 1.38 (s, 3H), 1.44 (s, 9H), 2.52-2.57 (t, 2H, J = 8 Hz), 2.75-2.82 (m, 2H), 3.69 (s, 3H), 4.32- 4.35 (m, 1 H), 4.62-4.64 (m, 2H), 5.27-5.39 (m, 3H), 5.85-6.00 (m,1 H); FAB HRMS: expected(M+Cs)=508.0770, found(M+Cs)=508.0750.
(ii) S-[2-(Methoxycarbonyl)ethyl]-D-penicillamine allyl ester, trifluoroacetate salt.
To a solution of N-(tert-butoxycarbonyl)-S-[2-(methoxycarbonyl)ethyl]-D- penicillamine allyl ester (2.00g., 5.51 mmol) in dichloromethane (25 mL) at 0 °C was added trifluoroacetic acid (6.7 mL) added. After 10 minutes, the solution was allowed to warm to room temperature. After 2.5 hours, the solution was concentrated and then azeotroped with benzene to give S-[2- (methoxycarbonyl)ethyl]-D-penicillamine allyl ester as a trifluoroacetate salt in 95% yield: 1H-NMR (CDCI3) δ 1.37 (s, 3H), 1.59 (s, 3H), 2.54-2.87 (2m, 4H), 3.71 (s, 3H), 4.13 (s,1 H), 4.69-4.74 (m, 2H), 5.31 (d, 1 H, J = 9.5 Hz), 5.39 (d, 1 H, J = 17.3 Hz), 5.88-5.97 (m, 1 H); FAB HRMS: expected(M+H)=276.1270, found(M+H)=276.1263.
(iii) N-[4-(4-Fluorophenoxy)benzenesulfonyl]-S-[2-(methoxycarbonyl)ethyl]-D- penicillamine allyl ester
To a solution of S-[2-(methoxycarbonyl)ethyl]-D-penicillamine allyl ester, trifluoroacetate salt (0.500g., 1.29 mmol) in dichloromethane (3 mL) at 0 °C was added DBU (0.425 mL, 2.84 mmol) followed by 4-(4-[fluorophenoxy])phenyl sulfonyl chloride(0.438 g., 1.74 mmol). The solution was stirred at 0 °C for 10 minutes and then was allowed to warm to room temperature. After 15 hours, the solution was concentrated, and the residue was purified on silica eluting with 10 -> 25%o ethyl acetate in hexane to give N-[4-(4-fluorophenoxy)benzenesulfonyl]-S-[2- (methoxycarbonyl)ethyl]-D-peniciiiamine allyl ester as a white solid in 66 % yield:
1H NMR (CDCI3) δ 1.36 (s, 3H), 1.40 (s, 3H), 2.47-2.53 (m,2H), 2.72-2.76 (m, 2H), 3.70 (s, 3H), 3.83 (d, 1 H, J = 10 Hz), 4.29-4.42 (m, 2H), 5.22 (d, 1 H, J = 5 Hz), 5.27 (d, 1 H, J = 12 Hz), 5.54 (d, 1 H, J = 10 Hz), 5.68-5.78 (m,1 H), 6.95-7.79 (m, 8H); FAB HRMS: expected(M+Cs) = 658.0346, found (M+Cs) = 658.0370. Example 8. Preparation of Compounds of Formula lll-A Example 8(a). S-[2-Hydroxyethyl]-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D- penicillamine {lll-A, W = HO(CH2)2S, Z = F}
Deprotection of S-[2-hydroxyethyl]-N-[4-(4-fluorophenoxy)benzenesulfonyl]- D-penicillamine allyl ester was carried in the same manner as in example 7. Purification on silica, eluting with 10% methanoi in dichloromethane provided S-[2- hydroxyethyl]-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D-penicillamine as a white solid in 61 % yield: mp 198-200 (decomp); 1H-NMR (MeOD) δ 1.36 (s, 3H), 1.40 (s, 3H), 2.58-2.74 (m, 2H), 3.60 (t, 2H, J=7 Hz), 3.66 (s, 1 H), 7.04-7.88 (m, 8H). Anal. calc. for C19H22FNO6S2«0.5CH2C2: C, 48.19; H, 4.77; N, 2.88. Found: C, 48.44; H. 4.71 ; N, 2.93. The starting material was prepared as follows: (i) N-[4-(4-fluorophenoxy)benzenesulfonyl]-D-penicillamine allyl ester.
To a stirred solution of N-[4-(4-fluorophenoxy)benzenesulfonyl]-S-[2- (methoxycarbonyl)ethyl]-D-penicillamine allyl ester (0.100g., 0.19 mmol) in DMSO(1 ml.) at room temperature was added sodium thiomethoxide (0.053g., 0.762 mmol). After 3.5 hours, the reaction was then acidified with 1 N aqueous sodium bisulfate to pH=4 and extracted with ethyl acetate. The organic phase was washed with brine, dried over MgS04, and concentrated. The residue was purified on silica eluting with 20% ethyl ethyl acetate in hexane to give N-[4-(4- fluorophenoxy)benzenesulfonyl]-D-penicillamine allyl ester as a colorless oil in 75% yield. 1H-NMR (δ, CDCI3) δ*1.43 (s, 6H), 1.93 (s,1 H), 3.82-3.86 (d, 1 H, J=11 Hz),4.25-4.38 (m, 2H), 5.23-5.29 (m, 2H), 5.49-5.53 (d, 1 H, J=11 Hz), 5.63-5.78 (m,1 H), 6.96-7.79 (m, 8H)
(ii) S-[2-Hydroxyethyl]-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D- penicillamine allyl ester.
To a 0 °C solution of N-[4-(4-fluorophenoxy)benzenesulfonyl]-D- penicillamine allyl ester (0.200g., 0.456 mmol) in DMF (2 mL) was added DBU (0.102 ml., 0.68 mmol), followed by 2-bromoethanol (0.049 ml., 0.68 mmol). After 1 hour at 0 °C and 5 hours at room temperature, the reaction was partitioned between brine and ethyl acetate. The organic layer was washed with brine, dried over Na2S04, and concentrated. Purification of the residue on silica, eluting with 20% ethyl acetate in hexane followed by 10% methanoi/ methylene chloride, provided S-[2-hydroxyethyl]-N-[4-(4-fluorophenoxy)benzenesulfonyl]-D- penicillamine allyl ester as a white solid in 72% yield. 1H-NMR (CDCI3) δ 1.39 (s, 3H), 1.40 (s, 3H), 2.75-2.80 (m, 2H), 3.67-3.78 (m,2H), 3.87 (d,1 H, J=10 Hz), 4.25- 4.38 (m,2H), 5.22-5.29 (m,2H), 5.66-5.76 (m,1 H), 5.93 (d,1 H, J=10 Hz), 6.95-7.77 (m, 8H); FAB HRMS: expected(M+Cs)=616.0240, found(M+Cs)=616.0265 The following was prepared in a similar manner:
Example 8(b) S-[2-(Aminocarbonyl)ethyl]-N-[4-(4-fluorophenoxy)benzene- sulfonyl]-D-penicillamine {lll-A, W = H2N(O=)C(CH2)2S, Z = F} mp 186-187 °C (decomp); 1H-NMR (CD3OD) δ 1.37 (s, 3H), 1.43 (s, 3H), 2.40- 2.44 (m,2H), 2.72-2.91 (m, 2H), 3.60 (s, 1 H), 7.02-7.87 (m, 8H). Example 9. Preparation of Compounds of Formula ll-A
Example 9(a) 2(S)-N-Hydroxy-3-methyl-3-methylsulfanyl-2-[(4-phenoxy- benzenesulfonyl)amino]butanamide {ll-A, W = CH3S, Z = H}
To a solution of S-methyl-N-[4-(phenoxy)benzenesulfonyl]-D-penicillamine (75 mg., 0.190 mmol) and DMF (0.003 mL., 0.04 mmol) in 1 mL of dichloromethane at -75 °C was added dropwise oxalyl chloride (0.022 mL., 0.247 mmol). The solution was stirred at -75 °C for 15 minutes and then allowed to warm to -25 °C over 45 minutes. The ice bath was then removed, and THF(1 mL.)
was added, followed by aqueous hydroxylamine (0.126 mL., 1.90 mmol, 50% sol'n.). The mixture was stirred at room temperature for 2 hours and then partitioned between ethyl acetate and 0.5 N aqueous sodium bisulfate. The organic later was washed with brine, filtered over celite, concentrated, and the residue was azeotroped with benzene. Trituration of the residue with 25% diethyl ether in hexane provided 2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4- phenoxybenzenesulfonyl)amino]butanamide as a white solid in 74 % yield: mp
161-163 °C; 1H NMR (DMSO-d6) δ 1.25 (s, 3H), 1.28 (s, 3H), 1.97 (s,3H), 3.62-
3.66 (m,1 H), 7.09-8.91 (m, 10H); FAB HRMS: expected(M+H)=411.1048, found(M+H)=411.1062.
Anal. calc. for C18H22N205S2: C, 52.66; H, 5.40; N, 6.82. Found: C, 52.58; H, 5.35;
N, 6.75.
Prepared in a similar fashion were the following:
Example 9(b) 2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4-(4- chlorophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = CH3S, Z = Cl} mp 194-195 °C; 1H-NMR (MeOD) δ 1.34 (s, 3H), 1.36 (s„ 3H), 2.01 (s,3H), 3.59
(s,1 H), 7.09-7.88 (m, 9H).
Anal. calc. for C18H21CIN205S2: C, 48.59; H, 4.76; N, 6.30. Found: C, 48.49; H,
4.75; N, 6.21.
Example 9(c) 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsuifanyl-
2-[(4-(4-fluorophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = (5- methylisoxazol-3-yl)CH2S, Z = F} mp 159 °C; Η NMR (DMSO-d6) δ 1.3 (s, 3H), 1.33 (s, 3H), 2.42 (s,3H), 3.70-3.83 (m,
3H), 6.20 (s, 1 H), 7.09 (d, J = 8 Hz, 2H), 7.2-7.4 (2 m, 4H), 7.83 (d, J = 7 Hz, 2H),
8.08 (d, J = 9 Hz, 1 H), 8.94 (s, 1 H), 10.67 (s, 1 H).
Anal. calc. for C22H24FN306S2: C, 51.86; H, 4.75; N, 8.25; Found: C, 51.86; H,
4.75; N, 8.25.
Example 9(d) 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl- 2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = (5- methylisoxazol-3-yl)CH2S, Z = Br} mp 154°C; 1 H-NMR (DMSO-d6) δ 1.31 (s, 3H), 1.33 (s, 3H), 2.42 (s,3H), 3.70-3.82
(m, 3H), 6.22 (s, 1 H), 7.10-7.18 (overlapping d, J = 9.1 , 8.8 Hz, 4H), 7.65 (d, J = 8.5
Hz, 2H), 7.85 (d, J = 8.5 Hz, 2H), 8.12 (d, J = 9.1 Hz, 1 H), 10.68 (s, 1 H).
Anal. calc. for C22H24BrN306S2: C, 46.32; H, 4.24; N, 7.37; Found: C, 46.19; H,
4.29; N, 7.18.
Example 9(e) 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W=(pyrid-2- yl)CH2S, Z=Br} mp 70-73 °C; 1 H-NMR (CDCI3) δ 1.21 (s,3H), 1.62 (s, 3H), 3.82-3.89 (m, 3H),
4.92 (d, J=5 Hz, 1 H), 5.98 (d, J=5 Hz, 1 H), 6.85-7.14 (m, 4H), 7.41-7.95 (m, 7H),
8.42 (br s, 1 H)
Anal. calc. for C23H24N3O5S2Br»0.4 H2O*0.5 hexane: C, 49.43, H 4.79, N 7.06.
Found: C, 49.50; H, 4.38; N, 6.90
Example 9(f) 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4- iodophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W=(pyrid-2-yl)CH2S,
Z=l} mp 85-87 °C; 1H-NMR (CDCI3) δ 1.55 (s, 3H), 1.63 (s, 3H), 3.84-3.97 (m, 2H),
4.96 (d, J=5.5 Hz, 1 H), 5.45 (d, J=5.6 Hz, 1 H), 5.97 (d, J=4.6Hz, 1 H), 6.83-7.26
(m, 4H), 7.68-7.89 (m, 8H), 11.22 (s, 1 H)
Anal.calc. for C23H24N305S2l: C, 45.30; H, 4.30; N, 6.40. Found: C, 45.33;
H, 4.12; N, 6.31.
Example 9(g) 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4- methylphenoxy)benzenesulfonyl)amino]butanamide {ll-A, W=(pyrid-2- yl)CH2S, Z=CH3} mp 105-108 °C; 1H-NMR (CDCI3) δ 1.54 (s, 3H), 1.68 (s, 3H), 2.40 (s, 3H), 3.85-
4.01 (m, 3H), 4.95 (d, J=6.0 Hz, 1 H), 5.45 (d, J=5.5 Hz, 1 H), 5.89 (d, J=6.2Hz,
1 H), 6.98-7.03 (m, 4H), 7.18-7.22 (m, 2H), 7.26-7.86 ( m, 4H), 8.47 (d, 4.6Hz, 2H)
Anal. calc. for C24H27N3O5S2*0.1 hexane* 1.1 AcOH: C, 55.64; H, 5.66; N, 7.35
Found: C, 55.62; H, 5.78; N, 7.38
Example 9(h) 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4- fluorophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W=(pyrid-2-yl)CH2S, Z=F} mp 66-69°C; 1H-NMR (CDCI3) δ 1.23 (s, 6H), 3.38 (m, 2H), 4.89-4.91 (d, J=7.5Hz,
1 H), 5.58-5.59 (d, J=10.2 Hz,1 H), 5.98-6.01 (d, J=7.5 Hz, 1 H), 6.97-7.11 (m, 4H),
7.58-8.13 (m, 6H), 8.41 (s, 2H).
Anal. calc. for C23H24N3O5S2F*0.2 H2O«0.2 hexane: C, 55.96; H, 5.52; N,
7.77. Found: C, 55.90; H, 5.47; N, 7.67.
Example 9(i) 2(S)-N-hydroxy-3-methyl-3-benzylsulfanyl-2-[(4- phenoxybenzenesulfonyl)amino]butanamide {ll-A, W = PhCH2S, Z = H} mp 35-37 °C; 1H-NMR (CDCI3) δ 1.21 (s, 3H); 1.61 (s, 3H), 3.62-3.82 (m, 2H),
6.98-7.04 (m, 6H), 7.21-7.54 (m, 6H), 7.89-7.91 (m, 2H).
Anal. calc. for C24H26N2O5S2*0.65H2O*0.2NH3: C, 57.45; H, 5.61 ; N, 6.14.
Found: C, 57.42; H, 5.59; N, 6.11
Example 9(j) 2(S)-N-hydroxy-3-methyl-3-(t-butoxycarbonyl)methylsulfanyl-2-
[(4-(4-fluorophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W=t-
BuO2CCH2S, Z=F} mp 138°C; 1 H-NMR (DMSO-d6) δ 1.28 (s, 6H), 1.45 (s, 9H), 3.38 (s, 1 H), 3.67 (d,
J = 9.6 Hz, 1 H), 7.09 (d, J = 8.8 Hz, 2H), 7.20-7.36 (2m, 4H), 7.81 (d, J = 8.8 Hz,
2H), 8.02 (d, J = 9.9 Hz, 1 H), 8.90 (s, 1 H), 10.60 (s, 1 H).
Anal. calc. for C23H29FN207S2: C, 52.26; H, 5.53; N, 5.30. Found: C, 52.21 ; H,
5.54; N, 5.21.
Example 9(k) 2(S)-N-hydroxy-3,3-dimethyl-2-[(4-phenoxybenzenesulfonyl)- amino]butanamide {ll-A, W = CH3, Z = H} mp 129-132°C; 1H-NMR (CDCI3) δ 0.92 (s, 9H), 3.32 (s, 1 H), 5.60 (br, 1 H), 6.99-
7.18 (m, 4H), 7.21-7.42 (m, 4H), 7.77 (d, J = 9.0 Hz, 2H).
Anal. calc. for C18H22N2O5S«0.3 H20: C, 56.32; H, 5.93; N, 7.30; Found: C,
56.31 ; H, 6.03; N, 7.68
Example 9(l) 2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-fluorophenoxy)benzene- sulfonyl)amino]butanamide {ll-A, W = CH3, Z = F} mp 122-125 °C; Η-NMR (CDCI3) δ 0.98 (s, 9H), 3.29 (d, J = 9.6 Hz,1 H), 5.60 (d, J =
10.5 Hz, 1 H), 6.97-7.09 (m, 6H), 7.77 (d, J = 8.5 Hz, 2H).
Anal. calc. for C18H21FN205S: C, 54.53; H, 5.34; N, 7.07 Found: C, 54.43; H,
5.33; N, 7.13
Example 9(m) 2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4- chlorophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = CH3, Z =
Cl} mp 164-165 °C; 1H-NMR(CD3OD): 1.00 (s, 9 H), 3.30 (s, 1 H), 7.08-7.86 (m,
8H); FAB HRMS: expected(M+H)=413.0938, Found(M+H)=413.0951.
Anal. calc. for C18H21CIN205S: C, 52.36; H, 5.13; N, 6.79 Found: C, 52.21 ;
H, 5.23; N, 6.66.
Example 9(n) 2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-2-yl)- methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = {1 - methyl-1 H-imidazol-2-yl)CH2S, Z = Br}: 1H NMR (DMSO): δ 1 ,23 (s, 3H),
1.28 (s, 3H), 3.32 (s, 3H), 3.67 (d, 1 H, J = 9.9 Hz), 3.80 (d, 1 H, J = 13.6 Hz, AB), 3.90 (d, 1 H, J = 13.6 Hz, AB), 6.77 (s, 1 H), 7.04-7.12 (m, 5H), 7.59 (d,
2H, J = 9.0 Hz), 7.76 (d, 2H, J = 8.7 Hz), 8.05 (d, 1 H, J = 9.9 Hz), 9.10 (s,
1 H), 10.96 (s, 1 H).
ESIMS Calcd for C22H25BrN405S2: 569/571. Found: 569/571.
Examples 9(o) through 9(s) may be prepared in a similar fashion:
Example 9(o) 2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-2-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide
{ll-A, W = (1 -methyl-1 H-imidazol-2-yl)CH2S, Z = Br}
Example 9(p) 2(S)-N-hydroxy-3-methyl-3-(1 H-imidazol-4-yl)methylsulfanyl-2-
[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = (1H- imidazol-4-yl)CH2S, Z = Br}
Example 9(q) 2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-4-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide
{ll-A, W = (1 -methyl-1 H-imidazol-4-yl)CH2S, Z = Br}
Example 9(r) 2(S)-N-hydroxy-3-methyl-3-(4-methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide
{ll-A, W = (4-methyl-4H-[1,2,4]-triazol-3-yl)CH2S, Z = Br}
Example 9(s) 2(S)-N-hydroxy-3-methyl-3-(1 -methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl-2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide {ll-A, W = (1-methyl-4H-[1 ,2,4]-triazol-3-yl)CH2S, Z = Br}
Examples 10(a), 10(b), and 10(c) were prepared in a manner similar to that described in Example 9(a).
Example 10(a) 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3- yl)methylsulfanyl-2-[(4-(pyrid-4-yloxy)benzenesulfonyl)amino]butanamide
Prepared according to the procedure described in Example 9(a): mp 71-72 °C. 1H NMR (CD3OD) δ 1.4 (s, 3H), 1.6 (s, 3H), 2.4 (s, 3H), 3.68 (s, 1 H), 3.78 (d, 2H, J = 10.6 Hz), 6.08 (s, 1 H), 7.08 (d, 2H, J = 5.0 Hz), 7.26 (d, 2H, J = 9.0 Hz), 7.94 (d, 2H, J = 9.0 Hz), 8.44 (d, 2H, J = 6.2 Hz).
Anal. Calcd for C21H24O6N4S2«0.5 H20*1.1 HOAc: C, 49.09; H, 5.22; N, 9.87; S, 11.30. Found: C, 49.33; H, 5.23; N, 9.69; S, 10.94. Example 10(b) 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3- yl)methylsulfanyl-2-[(4-{(pyrid-4- yl)sulfanyl}benzenesulfonyl)amino]butanamide
1H NMR (acetone-d6): δ 1.36 (s, 3H), 1.40 (s, 3H), 2.38 (s, 2H), 3.75 (d, 1 H, J = 13.4 Hz), 3.83 (d, 1 H, J = 13.4 Hz), 3.88 (s, 1 H), 6.18 (s, 1 H), 7.10-7.22 (m, 2H), 7.68 (d, 2H, J = 7.4 Hz), 7.94 (d, 2H, J = 7.4 Hz), 8.35-8.50 (m, 2H). IR: 3222, 1670, 1578, 1332, 1165 cm"1. HR FABMS: Calcd for C21H24N405S3Cs (M+Cs+): 640.9963. Found: 640.9988. Anal. Calcd for C21H24N405S3 • 0.1 C7H16 • 0.3 CHCl3: C, 47.66; H, 4.71 ; N, 10.10; S, 17.35. Found: C, 47.67; H, 4.69; N, 10.05; S, 17.42.
Example 10(c) 2(S)-N-hydroxy-3,3-dimethyl-2-[4-(pyrid-2-yl)oxybenzene- sulfonyl)amino]butanamide
mp 186-187 °C; 1H NMR (CD3OD) δ 1.01 (s, 9H), 3.30 (s, 1 H), 7.15-8.22 (m, 8 H);
FAB HRMS: expected(M+Cs)=512.0256, Found(M+Cs)=512.0267
Example 11. 2(S), S(R/S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsuIfinyl-2-
[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide
To a 0 °C solution of 2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl- 2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide (57 mg) in dichloromethane (1 mL) was added 17 mg of m-chloroperbenzoic acid. The mixture was allowed to warm slowly to room temperature overnight, and then partitioned between ethyl acetate and sat. aq. sodium bicarbonate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was purified by chromatography on silica gel, eluting first with ethyl acetate and then with 10% methanoi in dichloromethane. The product fractions were concentrated and then triturated with t-butyl methyl ether/hexane to give 23.8 mg (41 %) of 2(S), S(R/S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfinyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide as a white solid: mp 103- 105°C; H-NMR (CDCI3) δ 1.21 (s, 3H), 1.25 (s, 3H), 4.09-4.14 (m,3H), 4.65 (d, J=6.0 Hz, 1 H), 5.62 (d, 1 H), 6.02 (br 1 H), 6.91-7.00 (m, 5H), 7.40-7.47 (m, 6H), 8.52 (s, 2H), 10.02 (s, 1 H).
Example 12. 2(S)-N-hydroxy-3-methy l-3-(carboxymethy l)sulfany l-2-[(4-(4- fluorophenoxy)benzenesulfonyl)amino]butanamide
To a solution of 59.5 mg (0.113 mmol) of 2(S)-N-hydroxy-3-methyl-3-(t-
butoxycarbonyl)methylsulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)amino] butanamide (Example 9(j)) in dichloromethane (1.1 mL) at 20 °C was added trifluoroacetic acid (0.26 mL). After 16 hours, an additional 0.1 mL of trifluoroacetic acid was added. After an additional 6 hours, the reaction was diluted with 5 mL of benzene and then concentrated. The residue was purified by chromatography on silica gel, eluting with 5% methanoi in chloroform containing
0.1 % acetic acid, to give 28.9 mg (54%) of 2(S)-N-hydroxy-3-methyl-3-
(carboxymethyl)sulfanyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)-
1 aminojbutanamide as an off-white solid: mp 180°C; H-NMR (DMSO-d6) δ 1.19
(s, 3H), 1.25 (s, 3H), 3.03 (d, J = 16.9 Hz, 1 H), 3.13 (d, J = 16.9 Hz, 1 H), 3.85-4.00
(br s, 1 H), 7.08 (d, J = 8.8 Hz, 2H), 7.2-7.36 (2m, 4H), 7.77 (d, J = 8.8 Hz, 2H),
8.30-8.50 (br s, 1 H), 8.70-8.90 (br s, 1 H), 11.90-12.20 (br s, 1 H).
Anal. calc. for C19H21FN2O7S2*0.5 H2O»0.5 CHCI3: C, 43.28; H, 4.19; N, 5.17.
Found: C, 43.36; H, 4.40; N, 4.91.
The results obtained during biological testing of some preferred embodiments of the inventive compounds are described below.
BIOLOGICAL DATA Isolation of MMP's for Assays
The catalytic domain of human collagenase-1 was expressed as a fusion protein with ubiquitin in E. coli (see Gehring, E.R., J Biol. Chem., 1995, 270, 22507). After purification of the fusion protein, the fibroblast collagenase-1 catalytic domain (HFC) was released either by treatment with purified, active stromelysin-1 (1 :50 w/w ratio), which generated nearly 100% N-terminal Phe1 , or by autoprocessing the concentrated collagenase-1 fusion and then incubating at
37 °C for 1 hour. Final purification was completed using zinc chelate chromatography.
The propeptide and catalytic domain of human collagenase-3 (Coll3) was expressed in E. coli as an N-terminal fusion protein with ubiquitin. After purification of the fusion from inclusion bodies, the catalytic domain was liberated by treatment with 2mM APMA at room temperature overnight. Final purification was completed using copper chelate chromatography.
The catalytic domain of human stromelysin (Sin) was obtained by expression and purification of a C-ter minally truncated prostromelysin-1 from E. coli host BL21 (see Marcy et al. Biochem., 1991 , 30, 6476). The subsequent activation of the mature form (Sin) was completed with 2mM APMA for 1 hour at 37 °C, followed by separation using a sizing column.
Human matrilysin (Matr) was expressed in E. coli as a fusion protein with ubiquitin. After purification of the matrilysin/ubiquitin fusion from inclusion bodies, the catalytic domain was liberated by treatment with 2mM APMA at 37 °C for 2 hours. Final purification was complete using copper chelate chromatography.
The catalytic and fibronectin-like portion of human progelatinase A (GelA) was expressed as a fusion protein with ubiquitin in E. Coli . Assays were carried out on autocatalytically activated material.
Compounds of Formula I exhibited the ability to inhibit MMPs when tested in the following assay. In Vitro Assay Procedure
Assays were performed in assay buffer (50 mM Tricine pH 7.5, 200 mM sodium chloride, 10 mM calcium chloride, 0.5 mM zinc acetate containing 2% dimethyl sulfoxide (DMSO)) once the substrate and inhibitor were diluted into it. Stock solutions of inhibitors were prepared in 100% DMSO. Stock solutions of the substrate were prepared in 100% DMSO at a concentration of 6 mM.
The assay method was based on the hydrolysis of MCA-Pro-Leu-Gly-Leu- DPA-Ala-Arg-NH2 (American Peptide Co.) at 37 °C (see Knight, C.G. et al., FEBS, 1992, 296, 263-266). The fluorescence changes were monitored with a Perkin- Elmer LS-50B fluorimeter using an excitation wavelength of 328 nm and an emission wavelength of 393 nm. The substrate concentration used in the assays was 10 μM. The inhibitor was diluted into the assays from a solution in 100%
DMSO, and controls substituted an equal volume of DMSO so that the final DMSO concentration from inhibitor and substrate dilution in all assays was 2%. The concentration of enzyme in the assay ranged from 60 pM for gelatinase A to 1.5 nM for stromelysin and is a function of the enzymes respective kca^/Km for the MCA peptide substrate. Proper determination of steady-state rates of substrate cleavage required assay lengths of 60 minutes to allow for complete equilibration of the enzyme-inhibitor complex.
The Km for the MCA peptide substrate with the matrix metalloproteinases is quite high and exceeds its solubility under assay conditions. Consequently, the apparent K, (Ki,app) was determined to describe the strength of inhibition. However, in this case, K, app would be essentially equal to K, since [S]«Km. For the determination of Kι app, the concentration of the inhibitor was varied at a constant and low concentration of substrate and the steady-state rates of fluorescence change determined. In most cases absorptive quench due to the presence of ligand was not observed. For slow-binding inhibitors, onset of inhibition curves were collected for at least 45 minutes so that equilibrium was established. Steady- state rates of fluorescence change were obtained by fitting a curve to an equation for a single exponential decay containing a linear phase. The fitted value of the linear phase was taken as the steady-state rate. The steady-state rates were fitted to the Michaelis equation describing competitive inhibition by non-linear methods. Data resulting from tight-binding inhibition was analyzed, and Kι app determined by fitting the data to the tight-binding equation of Morrison (Biochem. Biophys. Ada, vol. 185, pp. 269-286 (1969)) by non-linear methods.
The results of the above-described tests are presented below in Table 1. All Ki values are in nM units.
TABLE 1
Example 13. Comparative Example
The compound of Example 9 from WO 95/35276, N-hydroxy-2-(toluene-4- sulfonylamino)acetamide (compound 13 shown below in Table 2), was prepared and its Ki's against gelatinase A and Stromelysin were determined. Table 2 shows these results in comparison to the results obtained for representative preferred compounds from the present invention.
TABLE 2
Thus, the compounds of Examples 9d, 9e, and 9m are 3400 to 500,000 times more potent as inhibitors of stromelysin and gelatinase A than the composition of Example 13, not according to the invention.
Claims (24)
1. A compound of formula I:
wherein:
Y is O or S;
Ar is an aryl group or a heteroaryl group;
R is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or -C(0)R1, wherein R., is hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or NR2R3, wherein R2 and R3 independently are hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;
X is -NH-OH or -OH; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
2. A compound according to claim 1 , wherein Ar is an aryl group substituted with a suitable substitutent in the position para to the Y moiety; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
3. A compound according to claim 2, wherein said suitable substituent is a halogen, an alkyl group, an O-alkyl group, an aryl group, a heteroaryl group, or an S-alkyl; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
4. A compound according to claim 1 , wherein R is an alkyl group; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
5. A compound according to claim 4, wherein R is the alkyl group -C(CH3)2- S-alkyl; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
6. A compound according to claim 5, wherein R is the alkyl group -C(CH3)2- S-CH2-heteroaryl; or a pharmaceutically acceptable prodrug, salt or solvate thereof.
7. A compound according to claim 1 , wherein Y is O.
8. A compound according to claim 1 , wherein Y is S.
9. A compound according to claim 1 , wherein said compound has the formula la:
or a pharmaceutically acceptable prodrug, salt or solvate thereof.
10. A compound according to claim 1 , wherein said compound is selected from:
2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-fluorophenoxy)benzenesulfonyl)- aminojbutanamide,
2(S)-N-hydroxy-3,3-dimethyl-2-[(4-(4-chlorophenoxy)benzenesulfonyl)- aminojbutanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-fluoro- phenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-bromophen- oxy)benzenesulfonyl)amino]butanamide,
N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(1-benzyl-1 H-imidazol-2- yl)methyl]-D-penicillamine,
N-[4-(4-lodophenoxy)benzenesulfonyl]-S-[(pyrid-2-yl)methyl]-D- penicillamine,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-iodophen- oxy)benzenesulfonyl)amino]butanamide,
N-[4-(4-Bromophenoxy)benzenesulfonyl]-S-[(5-methylisoxazol-3-yl)methyl]- D-penicillamine,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4- fluorophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(pyrid-2-yl)methylsulfanyl-2-[(4-(4-methyl- phenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4- (pyrid-4-yloxy)benzenesulfonyl)amino]butanamide, 2(S)-N-hydroxy-3-methyl-3-(5-methylisoxazol-3-yl)methylsulfanyl-2-[(4- {(pyrid-4-yl)sulfanyl}benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 H-imidazol-4-yl)methylsulfanyl-2-[(4-(4- bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-2-yl) methylsulfanyl-2-[(4- (4-bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-1 H-imidazol-4-yl) methylsulfanyl-2-[(4- (4-bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(4-methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl- 2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-(1 -methyl-4H-[1 ,2,4]-triazol-3-yl) methylsulfanyl- 2-[(4-(4-bromophenoxy)benzenesulfonyl)amino]butanamide,
2(S)-N-hydroxy-3-methyl-3-methylsulfanyl-2-[(4-(4-chlorophenoxy)benzene- sulfonyl)amino]butanamide; and pharmaceutically acceptable prodrugs, salts, and solvates thereof.
11. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt or solvate thereof; and
(b) a pharmaceutically acceptable carrier, diluent, vehicle or excipient.
12. A method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt or solvate thereof.
13. A method according to claim 12, wherein the mammalian disease condition is tumor growth, invasion or metastasis.
14. A method according to claim 12 wherein the mammalian disease condition is osteoarthritis, rheumatoid arthritis, osteoporosis, periodontitis, or gingivitis.
15. A method according to claim 12 wherein the mammalian disease condition is chronic dermal wounds, corneal ulceration, or degenerative skin disorders.
16. A method according to claim 12 wherein the mammalian disease condition is multiple sclerosis or stroke.
17. A method according to claim 12 wherein the mammalian disease condition is atherosclerosis, glomerular disease, or Alzheimer's disease.
18. A method according to claim 12 wherein the mammalian disease condition is characterized by unwanted angiogenesis.
19. A method according to claim 12, wherein the mammalian disease condition is diabetic retinopathy, macular degeneration, angiofibromas, or hemangiomas.
20. A method according to claim 12, wherein the mammalian disease condition is mediated by matrix metalloproteinase activity.
21. A method according to claim 12, wherein the mammalian disease condition is mediated by TNF-╬▒ convertase activity.
22. A method of inhibiting the activity of at least one metalloproteinase which comprises contacting said at least one metalloproteinase with an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable prodrug, salt or solvate thereof.
23. A method according to claim 22, wherein said at least one metalloproteinase is a matrix metalloproteinase.
24. A method according to claim 22, wherein said at least one metalloproteinase is a TNF-╬▒ convertase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82531897A | 1997-04-01 | 1997-04-01 | |
US08/825318 | 1997-04-01 | ||
PCT/US1998/006365 WO1998043963A1 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6874498A true AU6874498A (en) | 1998-10-22 |
AU747280B2 AU747280B2 (en) | 2002-05-09 |
Family
ID=25243697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU68744/98A Ceased AU747280B2 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0973748A1 (en) |
JP (1) | JP2001521504A (en) |
KR (1) | KR20010005940A (en) |
AU (1) | AU747280B2 (en) |
BR (1) | BR9809062A (en) |
CA (1) | CA2285372A1 (en) |
NZ (1) | NZ338082A (en) |
WO (1) | WO1998043963A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2207849C2 (en) * | 1997-07-22 | 2003-07-10 | Шионоги & Ко., Лтд. | Composition for glomerulopathy treatment and prophylaxis, novel compounds comprising to thereof, pharmaceutical composition for inhibition of matrix metalloproteinases activity and composition for inhibition of collagenases of type iv |
NZ503945A (en) | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
NZ505968A (en) | 1998-02-04 | 2003-03-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6075136A (en) * | 1998-02-17 | 2000-06-13 | Incyte Pharmaceuticals, Inc. | Prostate-associated serine protease |
US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
CZ20013176A3 (en) | 1999-03-03 | 2002-04-17 | The Procter & Gamble Company | Compound producing metalloproteinase inhibitor, pharmaceutical preparation, and process for preparing thereof and a medicament |
NZ513830A (en) | 1999-03-03 | 2001-09-28 | Procter & Gamble | Dihetero-substituted metalloprotease inhibitors |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
CA2464727A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US7504537B2 (en) | 2001-12-27 | 2009-03-17 | Dainippon Sumitomo Pharma Co., Ltd. | Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient |
EP1511488B1 (en) * | 2002-06-12 | 2013-05-22 | Symphony Evolution, Inc. | Human adam-10 inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
WO2008070579A2 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
BR112021006407A8 (en) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | use of egfr inhibitors for keratoderms |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE182581T1 (en) * | 1994-06-22 | 1999-08-15 | British Biotech Pharm | METALLOPROTEINASE INHIBITORS |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6022893A (en) * | 1995-08-08 | 2000-02-08 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives |
DE69633947T2 (en) * | 1995-12-08 | 2005-12-01 | Agouron Pharmaceuticals, Inc., San Diego | Intermediates for the production of metalloproteinase inhibitors |
ATE359264T1 (en) * | 1996-01-23 | 2007-05-15 | Shionogi & Co | SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING SAME |
-
1998
- 1998-03-31 EP EP98914379A patent/EP0973748A1/en not_active Withdrawn
- 1998-03-31 WO PCT/US1998/006365 patent/WO1998043963A1/en not_active Application Discontinuation
- 1998-03-31 CA CA002285372A patent/CA2285372A1/en not_active Abandoned
- 1998-03-31 AU AU68744/98A patent/AU747280B2/en not_active Ceased
- 1998-03-31 BR BR9809062-3A patent/BR9809062A/en not_active IP Right Cessation
- 1998-03-31 JP JP54194598A patent/JP2001521504A/en not_active Ceased
- 1998-03-31 KR KR1019997009017A patent/KR20010005940A/en not_active Application Discontinuation
- 1998-03-31 NZ NZ338082A patent/NZ338082A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20010005940A (en) | 2001-01-15 |
JP2001521504A (en) | 2001-11-06 |
BR9809062A (en) | 2000-08-01 |
AU747280B2 (en) | 2002-05-09 |
EP0973748A1 (en) | 2000-01-26 |
CA2285372A1 (en) | 1998-10-08 |
WO1998043963A1 (en) | 1998-10-08 |
NZ338082A (en) | 2000-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU747280B2 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
US5985900A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
USH1992H1 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses | |
US6153757A (en) | Metalloproteinase inhibitors and intermediates useful for their preparation | |
US5753653A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
ES2236829T3 (en) | BETA-SULFONIL HYDROXAMIC ACIDS AS INHIBITORS OF THE METALOPROTEINS OF THE MATRIX. | |
AU725403B2 (en) | Thrombin inhibitors | |
US6765003B1 (en) | 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors | |
JP2006506326A (en) | Cysteine protease inhibitor | |
CA2241414A1 (en) | Thiol derivatives with metallopeptidase inhibitory activity | |
JP2011525487A (en) | A novel heterocyclic carboxamide for use as a thrombin inhibitor | |
US6500948B1 (en) | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof | |
MXPA99008995A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
CN101163678B (en) | Pyridylmethylsulfone derivative | |
AU763835B2 (en) | Heteroaryl succinamides and their use as metalloproteinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |